Supplementary Information for Synthesis of tert-alkylphosphonate oligonucleotides through light-driven radical-polar crossover

Kenji Ota, Kazunori Nagao, Dai Hata, Haruki Sugiyama, Yasutomo Segawa, Ryosuke Tokunoh, Tomohiro Seki, Naoya Miyamoto, Yusuke Sasaki, and Hirohisa Ohmiya

Table of Contents

■ Supplementary Methods ■ 1. Instrumentation and Chemicals S2 2. Characterization Data for Redox-Active Esters S3-S4 3. General Procedure for Synthesis of Phosphites S4 S5-S14 4. Characterization Data for Phosphites and the Synthetic Intermediates 5. General Procedure for Synthesis of *tert*-Alkylphosphonate Oligonucleotides S14 6. Characterization Data for Alkylated Products S14-S23 7. X-ray structures of **3aa** S24–S25 8. Derivatization of tert-Alkylphosphonates to the Phosphoramidites S26-S27 9. Characterization Data for Phosphoramidites S27-S29 10. Procedure for Automated Solid-Support Synthesis of Oligonucleotides S30-S47 11. Detection of Alkylsulfonium S48 12. Effects of Additives on Conversion of Redox-Active Esters S48 13. Comparison with Other Carbocation Methods S48-S49 14. The Effects of Chiral Leaving Groups S49 15. Examination of Catalytic Reactions S49-S50 16. Examination of the Addition of Trapping Reagent for Carbocation S50 17. Unsuccessful Substrates S51 ■ NMR Spectra ■ S52-S190 ■ Supplementary References ■ S191

■ Supplementary Methods ■

1. Instrumentation and Chemicals

NMR spectra were recorded on a Bruker AVANCE NEO 400N spectrometer, operating at 400 MHz for ¹H NMR, 100.6 MHz for ¹³C NMR, and 162 MHz for ³¹P NMR. Chemical shift values for ¹H and ¹³C are referenced to Me₄Si and the residual solvent resonances, respectively. Chemical shifts were reported in δ ppm. Mass spectra were obtained with Bruker Impact HD mass spectrometer (ESI). TLC analyses were performed on commercial glass plates bearing a 0.25-mm layer of Merck Silica gel 60F₂₅₄. Silica gel (Wakosil[®] 60, 64~210 µm) was used for column chromatography. Biotage Selekt was used for purification. Gilson GX-281 was used as a Preparative HPLC. The column was YMCActus Triant C18 (50×20 mmI.D., 5 µm) with a flow rate of 25 mL/min at room temperature. Melting points were measured on a Stanford Research Systems MPA100. Kessil A160WE 40W Tuna Blue (highest blue and intensity setting) was used as a light source. Techno Sigma UCR-150N was used as a cryocooler. TEKNOS MG9 was used as a fan.

For Prep-HPLC, Waters MS-trigger HPLC systems equipped with YMC-Actus Triart C18 (30 mm ID \times 100 mm L, 5 µm) column and Waters Acquity QDa MS detector were used. The eluent was 10mM NH₄HCO₃ aq./MeCN. GeneDesign ns8-II oligosynthesizer was used for the automated solid-support synthesis of oligonucleotides. Oligonucleotides were analyzed for characterization by a Waters Xevo G2-XS Qtof UPLC-MS system (ESI-Qtof) with a ACQUITY UPLC OST C18 (1.7 µm, 2.1 x 50 mm) column. The eluent was 240 mM hexafluoroisopropanol/7 mM triethylamine aqueous solution containing 5% MeOH and the methanolic solution (100% MeOH). For distillation of volatile components, a Thermo Scientific SAVANT SPD2010 SpeedVac Concentrator was used. Quantification of oligonucleotides was conducted based on UV absorbance measurement on Unchaind Labs LUNATIC.

All reactions were carried out under nitrogen atmosphere. Materials were obtained from commercial suppliers or prepared according to standard procedures unless otherwise noted. PTH1 and PTH3 were prepared by the reported procedure.¹ PTH2 was prepared by the methylation of benzo[b]phenothiazine with iodomethane.² **PTH4** was prepared by the reported procedure.³ LiBF₄, NaBF4 and LiPF6 were purchased from Tokyo Chemical Industry Co., stored under nitrogen, and used as received. MeCN, DCM, DMF, THF and toluene were purchased from FUJIFILM Wako Pure Chemical Co., stored under nitrogen, and used as received. Alcohol S1-1 was prepared by the reported procedure.⁴ Alcohol S1-2 was prepared by the reported procedure.⁵ Alcohol S1-3 was prepared by the reported procedure.⁶ Phosphordiamidite S2-3 was purchased from Tokyo Chemical Industry Co., stored under nitrogen, and used as received. Redox-active esters 2a-2k were prepared according to the reported procedure.7 Thymine was purchased from Tokyo Chemical Industry Co., stored under nitrogen, and used as received. 4CzIPN was prepared by the reported procedure.8 Trifluoroacetic acid (TFA) was purchased from Nacalai Tesque Inc., stored under nitrogen, and used as received. 2-Phenyl-2-propanol (5a) was purchased from Tokyo Chemical Industry Co., stored under nitrogen, and used as received. Trimethylsilyl trifluoromethanesulfonate (TMSOTf) was purchased from Tokyo Chemical Industry Co., zinc iodide (ZnI₂) was purchased from FUJIFILM Wako Pure Chemical Co., stored under nitrogen, and used as received. Phosphites 1g and 1h were purchased from Tokyo Chemical Industry Co., stored under nitrogen, and used as received.

2. Characterization Data for Redox-Active Esters

1,3-Dioxoisoindolin-2-yl 2-(4-Bromophenyl)-2-methylpropanoate (2b)



White solid. **M.p.** 125–127 °C. ¹**H NMR** (400 MHz, CDCl₃) δ7.88–7.85 (m, 2H), 7.80–7.76 (m, 2H), 7.56–7.52 (m, 2H), 7.39–7.35 (m, 2H), 1.76 (s, 6H). ¹³**C NMR** (100.6 MHz, CDCl₃) δ172.7, 161.9, 141.6, 134.7, 131.8, 128.9, 127.6, 123.9, 121.5, 46.0, 26.7. **HRMS–ESI** (*m/z*): [M+H]⁺ calcd for C₁₈H₁₅BrNO₄, 388.0179; found, 388.0187.

1,3-Dioxoisoindolin-2-yl 1-Phenylcyclobutane-1-carboxylate (2c)



White solid. **M.p.** 93–96 °C. ¹**H NMR** (400 MHz, CDCl₃) δ 7.86–7.84 (m, 2H), 7.77–7.75 (m, 2H), 7.45–7.40 (m, 4H), 7.32 (m, 1H), 3.11–3.04 (m, 2H), 2.74–2.67 (m, 2H), 2.25 (m, 1H), 2.01 (m, 1H). ¹³**C NMR** (100.6 MHz, CDCl₃) δ 172.2, 161.9, 141.1, 134.6, 129.0, 128.6, 127.4, 126.4, 123.8, 50.9, 32.6, 16.8. **HRMS–ESI** (*m/z*): [M+NH₄]⁺ calcd for C₁₉H₁₉N₂O₄, 339.1339; found, 339.1337.

1,3-Dioxoisoindolin-2-yl 1-Phenylcyclopentane-1-carboxylate (2d)



White solid. **M.p.** 84–87 °C. ¹**H NMR** (400 MHz, CDCl₃) δ 7.85–7.83 (m, 2H), 7.77–7.75 (m, 2H), 7.50–7.48 (m, 2H), 7.42–7.39 (m, 2H), 7.33 (m, 1H), 2.82–2.76 (m, 2H), 2.17–2.10 (m, 2H), 1.95–1.84 (m, 4H).¹³**C NMR** (100.6 MHz, CDCl₃) δ 172.6, 162.0, 141.1, 134.6, 129.0, 128.6, 127.4, 126.8, 123.8, 58.0, 37.1, 23.8. **HRMS–ESI** (*m/z*): [M+NH₄]⁺ calcd for C₂₀H₂₁N₂O₄, 353.1496; found, 353.1501.

1,3-Dioxoisoindolin-2-yl 4-Phenyltetrahydro-2H-pyran-4-carboxylate (2e)



White solid. **M.p.** 122–124 °C. ¹**H NMR** (400 MHz, CDCl₃) δ7.88–7.85 (m, 2H), 7.79–7.77 (m, 2H), 7.53–7.51 (m, 2H), 7.47–7.43 (m, 2H), 7.37 (m, 1H), 4.07–4.02 (m, 2H), 3.88–3.81 (m, 2H), 2.65–2.61 (m, 2H), 2.21–2.14 (m, 2H). ¹³**C NMR** (100.6 MHz, CDCl₃) δ171.0, 161.8, 140.7, 134.8, 129.0, 128.9, 128.0, 125.8, 123.9, 65.3, 48.9, 34.8. **HRMS–ESI** (*m*/*z*): [M+H]⁺ calcd for C₂₀H₁₈NO₅, 352.1179; found, 352.1175.

1,3-Dioxoisoindolin-2-yl 2,2-Diphenylpropanoate (2g)



White solid. **M.p.** 114–118 °C. ¹**H NMR** (400 MHz, CDCl₃) δ7.88–7.86 (m, 2H), 7.78–7.76 (m, 2H), 7.44–7.30 (m, 10H), 2.17 (s, 3H). ¹³C **NMR** (100.6 MHz, CDCl₃) δ171.9, 161.9, 142.3, 134.7, 129.0, 128.4, 128.0, 127.5, 123.9, 55.8, 27.1. **HRMS–ESI** (*m/z*): [M+NH₄]⁺ calcd for C₂₃H₂₁N₂O₄, 389.1496; found, 389.1506.

1,3-Dioxoisoindolin-2-yl 2-Methyl-2-phenoxypropanoate (2j)



White solid. **M.p.** 74–77 °C. ¹**H NMR** (400 MHz, CDCl₃) δ7.92–7.89 (m, 2H), 7.81–7.79 (m, 2H), 7.35–7.31 (m, 2H), 7.11–7.06 (m, 3H), 1.79 (s, 6H). ¹³**C NMR** (100.6 MHz, CDCl₃) δ170.9, 161.8, 154.6, 134.8, 129.4, 128.9, 124.0, 123.2, 120.2, 78.6, 25.7. **HRMS–ESI** (*m/z*): [M+NH₄]⁺ calcd for C₁₈H₁₉N₂O₅, 343.1288; found, 343.1287.

3. General Procedure for Synthesis of Phosphites



Supplementary Fig. 1. Synthesis of phosphites

Synthesis of 1a-1 as a representative (Supplementary Fig. 1). Phosphordiamidite **S2-1** was prepared according to the literature.⁹ To a solution of 5'-*O*-TIPS thymidine (1.0 g, 2.5 mmol) and phosphordiamidite **S2-1** (0.94 g, 2.5 mmol) in MeCN (20 mL), 1-phenyl-1*H*-imidazol-3-ium trifluoromethanesulfonate (0.81 g, 2.75 mmol) was added. The reaction mixture was stirred for 3 h at room temperature under a nitrogen atmosphere. After the solvent was removed under reduced pressure, purification by flash column chromatography on silica gel (Biotage Selekt, 95:5–70:30, hexane/EtOAc) gave the phosphoramidite **S3-1** as a white amorphous solid (1.23 g, 1.82 mmol, 73%).

To a solution of phosphoramidite **S3-1** (1.22 g, 1.82 mmol) and 3'-O-Ac thymidine (0.57 g, 2.0 mmol) in MeCN (7 mL), 1*H*-tetrazole (0.14 g, 2.0 mmol) was added. The reaction mixture was stirred for 3 h at room temperature under a nitrogen atmosphere. After the filtrate was concentrated under reduced pressure, purification by flash column chromatography on silica gel (Biotage Selekt, 50:50:0-50:40:10, hexane/EtOAc/MeOH) gave the phosphite **1a-1** (1.37 g, 1.60 mmol, 88%) as a white amorphous solid.

4. Characterization Data for Phosphites and the Synthetic Intermediates 3-{[Bis(diisopropylamino)phosphaneyl]oxy}-3-phenylpropanenitrile (S2-1)



S2-1 was purified by flash chromatography on silica gel (70:29:1, hexane/EtOAc/NEt₃) (Supplementary Fig. 1; 10 mmol scale; 3.24 g, 8.58 mmol, 86% isolated yield). White solid. The spectrum data of **S2-1** was consistent with the literature.⁹

Phosphoramidite (S3-1)



S3-1 was purified by flash chromatography on silica gel (Biotage Selekt, 95:5–70:30, hexane/EtOAc) (Supplementary Fig 1; 2.5 mmol scale; 1.23 g, 1.82 mmol, 73% isolated yield). The ratio (2:2:1:1) of diastereomers was determined by ³¹P-NMR analysis. White amorphous solid. ¹H **NMR** (400 MHz, CDCl₃) δ 8.21 (brs, 1H), 7.48–7.31 (m, 6H), 6.37 (m, 0.33H), 6.15 (m, 0.67H), 5.00 (m, 1H), 4.65 (m, 0.33H), 4.40 (m, 0.67H), 4.11 (m, 0.33H), 4.01–3.87 (m, 1.33H), 3.81–3.51 (m, 3.34H), 2.82–2.75 (m, 2H), 2.47 (m, 0.33H), 2.27 (m, 0.33H), 2.15 (m, 0.67H), 1.96–1.81 (m, 3.67H), 1.28–0.96 (m, 33H). ¹³C **NMR** (100.6 MHz, CDCl₃) δ 163.6, 150.3, 150.2, 150.1, 140.1, 140.1, 139.9, 135.4, 135.4, 135.3, 128.7, 128.7, 128.6, 128.6, 126.1, 126.1, 126.1, 126.0, 116.9, 116.8, 116.8, 111.0, 110.8, 110.7, 86.8, 86.6, 86.6, 86.4, 86.4, 84.7, 84.6, 84.5, 73.7, 73.5, 73.3, 72.2, 72.0, 71.2, 71.0, 63.4, 63.3, 63.2, 43.5, 43.4, 43.3, 43.2, 40.1, 40.0, 39.9, 39.8, 39.8, 28.4, 28.4, 28.3, 28.3, 24.7, 24.6, 24.6, 24.6, 24.5, 24.5, 24.5, 24.4, 24.2, 24.1, 24.0, 18.0, 18.0, 12.3, 12.3, 11.8, 11.8 (only observed peaks). ³¹P NMR (162 MHz, CDCl₃) δ 149.8, 149.6, 148.3, 147.7. **HRMS–ESI** (*m/z*): [M+Na]⁺ calcd for C₃₄H₅₅N₄NaO₆PSi, 697.3521; found, 697.3526.

Phosphite (1a-1)



1a-1 was purified by flash chromatography on silica gel (Biotage Selekt, 50:50:0–50:40:10, hexane/EtOAc/MeOH) (Supplementary Fig. 1; 1.82 mmol scale; 1.37 g, 1.60 mmol, 88% isolated yield) The ratio (1.3:1.2:1.1:1) of diastereomers was determined by ³¹P-NMR analysis. White amorphous solid. ¹H NMR (400 MHz, CDCl₃) δ 9.09–8.90 (m, 2H), 7.52–7.28 (m, 7H), 6.34–6.21 (m, 2H), 5.40 (m, 1H), 5.19 (m, 1H), 4.83 (m, 1H), 4.17–3.53 (m, 6H), 2.94–2.75 (m, 2H), 2.43–2.04

(m, 7H), 1.99–1.88 (m, 6H), 1.14–1.05 (m, 21H). ¹³C NMR (100.6 MHz, CDCl₃) δ 170.7, 170.5, 170.4, 170.4, 163.7, 163.6, 150.3, 150.2, 139.3, 139.2, 138.9, 138.7, 136.2, 135.3, 135.2, 135.1, 135.0, 134.9, 129.4, 129.3, 129.2, 129.1, 125.9, 125.8, 116.7, 116.6, 116.6, 116.5, 111.6, 111.4, 111.4, 111.3, 111.1, 111.0, 111.0, 86.3, 85.9, 85.0, 84.7, 84.6, 84.5, 84.4, 83.4, 83.3, 83.2, 74.7, 74.4, 74.2, 74.1, 73.9, 73.8, 73.5, 73.4, 71.6, 71.6, 71.5, 71.4, 71.0, 70.9, 70.7, 70.7, 63.1, 63.0, 63.0, 62.6, 62.4, 62.3, 62.1, 40.0, 39.9, 39.7, 37.3, 37.2, 37.2, 37.1, 37.0, 28.1, 27.9, 21.0, 20.9, 18.0, 12.6, 12.6, 12.3, 11.8, 11.8 (only observed peaks). ³¹P NMR (162 MHz, CDCl₃) δ 140.0, 139.9, 139.9, 139.2. HRMS–ESI (*m/z*): [M+NH₄]⁺ calcd for C₄₀H₆₀N₆O₁₂PSi, 875.3771; found, 875.3772.

3-{[Bis(diisopropylamino)phosphaneyl]oxy}-3-methylbutanenitrile (S2-2)



S2-2 was purified by flash chromatography on silica gel (70:29:1, hexane/EtOAc/NEt₃) (Supplementary Fig. 1; 3.3 mmol scale; 789 mg, 2.4 mmol, 73% isolated yield). White solid. **M.p.** 57–59 °C. ¹**H NMR** (400 MHz, CDCl₃) δ 3.62–3.53 (m, 4H), 2.59 (s, 2H), 1.51 (s, 6H), 1.20–1.16 (m, 24H). ¹³C NMR (100.6 MHz, CDCl₃) δ 118.1, 74.2 (d, *J*_{C-P} = 17.4 Hz), 45.0 (d, *J*_{C-P} = 13.4 Hz), 32.9 (d, *J*_{C-P} = 4.9 Hz), 28.1 (d, *J*_{C-P} = 10.2 Hz), 24.4 (d, *J*_{C-P} = 5.7 Hz), 24.0 (d, *J*_{C-P} = 8.4 Hz). ³¹**P NMR** (162 MHz, CDCl₃) δ 99.6. **HRMS–ESI** (*m*/*z*): [M+H]⁺ calcd for C₁₇H₃₇N₃OP, 330.2669; found, 330.2675.

Phosphoramidite (S3-2)



S3-2 was purified by flash chromatography on silica gel (Biotage Selekt, 93:7–65:35, hexane/EtOAc) (Supplementary Fig. 1; 1.5 mmol scale; 621 mg, 0.99 mmol, 66% isolated yield). The ratio (1.2:1) of diastereomers was determined by ³¹P-NMR analysis. White amorphous solid. ¹H **NMR** (400 MHz, CDCl₃) δ 8.89 (brs, 1H), 7.45 (s, 1H), 6.34 (m, 1H), 4.54 (m, 1H), 4.13 (m, 1H), 4.00–3.85 (m, 2H), 3.67–3.58 (m, 2H), 2.66–2.40 (m, 3H), 2.07 (m, 1H), 1.90 (s, 3H), 1.52–1.50 (m, 6H), 1.22–1.09 (m, 33H). ¹³C **NMR** (100.6 MHz, CDCl₃) δ 163.8, 163.8, 150.3, 150.2, 135.3, 135.3, 117.4, 117.4, 110.8, 110.8, 86.9, 86.8, 86.6, 86.5, 84.9, 84.7, 74.1, 74.0, 74.0, 73.9, 73.0, 72.9, 72.8, 72.7, 63.5, 63.5, 43.3, 43.2, 40.1, 40.0, 39.8, 39.8, 32.9, 32.9, 32.9, 32.8, 28.4, 28.4, 28.3, 28.3, 24.5, 24.4, 24.4, 24.3, 24.3, 24.2, 24.1, 18.0, 18.0, 12.3, 11.8, 11.8 (only observed peaks). ³¹P **NMR** (162 MHz, CDCl₃) δ 139.5, 139.4. **HRMS–ESI** (*m/z*): [M+H]⁺ calcd for C₃₀H₅₆N₄O₆PSi, 627.3701; found, 627.3710.

Phosphite (1a-2)



1a-2 was purified by flash chromatography on silica gel (Biotage Selekt, 50:50:0–50:40:10, hexane/EtOAc/MeOH) (Supplementary Fig. 1; 0.6 mmol scale; 389 mg, 0.48 mmol, 80% isolated yield). The ratio (1.2:1) of diastereomers was determined by ³¹P-NMR analysis. White amorphous solid. ¹H NMR (400 MHz, CDCl₃) δ 8.15–8.08 (m, 2H), 7.44–7.38 (m, 2H), 6.37–6.30 (m, 2H), 5.28 (m, 1H), 4.95 (m, 1H), 4.27–3.94 (m, 6H), 2.65–2.64 (m, 2H), 2.48–2.37 (m, 2H), 2.25–2.11 (m, 5H), 1.94–1.90 (m, 6H), 1.60–1.56 (m, 6H), 1.17–1.09 (m, 21H). ¹³C NMR (100.6 MHz, CDCl₃) δ 170.5, 170.4, 163.7, 163.5, 150.4, 150.3, 135.2, 135.1, 134.9, 116.8, 116.7, 111.5, 111.4, 111.1, 111.0, 86.4, 86.4, 86.3, 84.6, 84.6, 84.5, 83.4, 83.3, 83.3, 75.7, 75.6, 75.5, 75.4, 74.2, 73.8, 73.5, 73.4, 73.1, 73.0, 63.2, 63.2, 61.4, 61.1, 40.0, 39.8, 37.3, 37.3, 32.9, 32.9, 30.9, 28.9, 28.8, 28.8, 28.7, 28.6, 20.9, 20.9, 18.0, 18.0, 12.6, 12.6, 12.3, 12.3, 11.8 (only observed peaks). ³¹P NMR (162 MHz, CDCl₃) δ 135.0, 134.6. HRMS–ESI (*m*/*z*): [M+H]⁺ calcd for C₃₆H₅₇N₅O₁₂PSi, 810.3505; found, 810.3497.

3-{[Bis(diisopropylamino)phosphaneyl]oxy}butanenitrile (S2-3)



S2-3 was purified by flash chromatography on silica gel (70:29:1, hexane/EtOAc/NEt₃) (Supplementary Fig. 1; 4 mmol scale; 505 mg, 1.6 mmol, 40% isolated yield). White solid. **M.p.** 41–45 °C. ¹**H NMR** (400 MHz, CDCl₃) δ4.00 (m, 1H), 3.58–3.48 (m, 4H), 2.64–2.54 (m, 2H), 1.38 (d, J = 6.4 Hz, 3H), 1.19–1.16 (m, 24H). ¹³**C NMR** (100.6 MHz, CDCl₃) δ117.6, 65.4, 65.2, 44.8, 44.6, 44.5, 26.6, 26.5, 24.4, 24.3, 24.2, 24.1, 24.1, 21.6, 21.6 (only observed peaks). ³¹**P NMR** (162 MHz, CDCl₃) δ113.2. **HRMS–ESI** (*m*/*z*): [M+H]⁺ calcd for C₁₆H₃₅N₃OP, 316.2512; found, 316.2513.

Phosphoramidite (S3-3)



S3-3 was purified by flash chromatography on silica gel (Biotage Selekt, 93:7–55:45, hexane/EtOAc) (Supplementary Fig. 1; 1 mmol scale; 251 mg, 0.41 mmol, 41% isolated yield). The ratio (1.3:1.2:1.1:1) of diastereomers was determined by ³¹P-NMR analysis. White amorphous solid. ¹H NMR (400 MHz, CDCl₃) δ 8.15 (brs, 1H), 7.45 (m, 1H), 6.33 (m, 1H), 4.58 (m, 1H), 4.18–4.07 (m, 2H), 4.00–3.86 (m, 2H), 3.66–3.57 (m, 2H), 2.66–2.38 (m, 3H), 2.10 (m, 1H), 1.91 (s, 3H), 1.41–

1.36 (m, 3H), 1.22–1.09 (m, 33H). ¹³C NMR (100.6 MHz, CDCl₃) δ 163.6, 150.2, 150.2, 150.1, 135.4, 135.4, 135.3, 135.3, 117.1, 117.1, 117.0, 110.9, 110.8, 110.8, 87.0, 87.0, 86.8, 86.8, 86.5, 86.5, 86.4, 84.8, 84.8, 84.6, 84.5, 73.5, 73.4, 73.3, 73.3, 73.2, 73.2, 66.2, 66.0, 65.9, 65.7, 65.6, 65.6, 65.4, 65.4, 63.5, 63.4, 63.3, 43.3, 43.3, 43.2, 43.2, 43.2, 43.1, 40.1, 40.1, 40.1, 40.0, 40.0, 39.9, 39.9, 26.9, 26.8, 26.8, 26.7, 26.7, 24.6, 24.5, 24.5, 24.5, 24.4, 24.4, 24.3, 22.0, 21.9, 21.9, 21.9, 18.0, 18.0, 18.0, 12.3, 12.3, 11.8 (only observed peaks). ³¹P NMR (162 MHz, CDCl₃) δ 147.4, 147.2, 147.1, 146.8. HRMS–ESI (*m/z*): [M+Na]⁺ calcd for C₂₉H₅₃N₄NaO₆PSi, 635.3364; found, 635.3361.

Phosphite (1a-3)



1a-3 was purified by flash chromatography on silica gel (Biotage Selekt, 50:50:0–50:40:10, hexane/EtOAc/MeOH) (Supplementary Fig. 1; 0.4 mmol scale; 305 mg, 0.38 mmol, 96% isolated yield). The ratio (1.1:1:1:1) of diastereomers was determined by ³¹P-NMR analysis. White amorphous solid. ¹H NMR (400 MHz, CDCl₃) δ 8.66–8.53 (m, 2H), 7.43–7.39 (m, 2H), 6.36–6.29 (m, 2H), 5.28 (m, 1H), 4.96 (m, 1H), 4.54 (m, 1H), 4.40–4.08 (m, 4H), 3.98–3.93 (m, 2H), 2.70–2.55 (m, 2H), 2.51–2.38 (m, 2H), 2.28–2.11 (m, 5H), 1.96–1.91 (m, 6H), 1.53–1.40 (m, 3H), 1.21–1.09 (m, 21H). ¹³C NMR (100.6 MHz, CDCl₃) δ 170.5, 170.5, 163.7, 163.6, 150.4, 150.3, 135.2, 135.2, 135.1, 134.9, 134.9, 134.9, 116.8, 116.7, 116.6, 111.6, 111.6, 111.5, 111.3, 111.1, 86.4, 86.4, 86.4, 86.3, 86.3, 84.7, 84.6, 84.6, 84.5, 83.4, 83.3, 83.3, 83.2, 74.2, 74.1, 74.1, 74.0, 73.9, 73.8, 73.7, 73.5, 73.4, 73.3, 66.5, 66.4, 66.3, 66.2, 66.1, 66.1, 65.9, 63.4, 63.2, 62.1, 62.1, 62.0, 61.9, 61.8, 61.8, 61.7, 40.0, 40.0, 39.9, 39.9, 39.8, 37.3, 37.2, 37.2, 27.0, 26.9, 26.9, 26.9, 26.8, 22.4, 22.4, 22.3, 22.3, 22.2, 20.9, 20.8, 18.0, 18.0, 12.7, 12.6, 12.3, 11.8 (only observed peaks). ³¹P NMR (162 MHz, CDCl₃) δ 139.7, 139.2, 139.1, 139.0. HRMS–ESI (*m*/*z*): [M+Na]⁺ calcd for C₃₅H₅₄N₅NaO₁₂PSi, 818.3168; found, 818.3167.

Phosphite (1a-4)



1a-4 was purified by flash chromatography on silica gel (Biotage Selekt, 50:50:0–50:40:10, hexane/EtOAc/MeOH) (Supplementary Fig. 1; 0.6 mmol scale; 403 mg, 0.52 mmol, 86% isolated yield). The ratio (1.1:1) of diastereomers was determined by ³¹P-NMR analysis. White amorphous solid. ¹H NMR (400 MHz, CDCl₃) δ 8.64 (brs, 2H), 7.42–7.38 (m, 2H), 6.36–6.29 (m, 2H), 5.29 (m,

1H), 4.95 (m, 1H), 4.20–4.04 (m, 6H), 3.98–3.91 (m, 2H), 2.71–2.68 (m, 2H), 2.49–2.39 (m, 2H), 2.27–2.11 (m, 5H), 1.94–1.91 (m, 6H), 1.19–1.08 (m, 21H). ¹³**C NMR** (100.6 MHz, CDCl₃) δ 170.7, 170.6, 170.5, 163.8, 163.7, 150.4, 150.3, 136.3, 135.3, 135.2, 135.0, 135.0, 117.2, 117.1, 111.6, 111.5, 111.4, 111.2, 111.2, 86.4, 86.4, 86.3, 86.0, 85.0, 84.8, 84.7, 84.6, 84.5, 83.4, 83.4, 83.3, 83.3, 74.7, 74.2, 74.1, 74.0, 73.8, 73.7, 63.1, 62.6, 62.3, 62.2, 62.2, 58.0, 57.8, 57.5, 57.4, 40.0, 39.9, 37.3, 37.2, 37.2, 21.0, 20.9, 20.4, 20.3, 20.3, 18.0, 18.0, 12.6, 12.6, 12.6, 12.3, 11.8 (only observed peaks). ³¹**P NMR** (162 MHz, CDCl₃) δ 139.7, 139.3. **HRMS–ESI** (*m*/*z*): [M+NH₄]⁺ calcd for C₃₄H₅₆N₆O₁₂PSi, 799.3458; found, 799.3459.

N-Benzoyl-5'-O-TIPS-5-methyl-2'-deoxycytidine



N-Benzoyl-5'-*O*-TIPS-5-methyl-2'-deoxycytidine was prepared according to the reported procedure⁹ and purified by flash chromatography on silica gel (Biotage Selekt, 50:50:0–50:45:5, hexane/EtOAc/MeOH) (3 mmol scale; 948 mg, 1.89 mmol, 63% isolated yield). White solid. **M.p.** 113–117 °C. ¹H NMR (400 MHz, CDCl₃) δ 13.3 (brs, 1H), 8.31 (d, *J* = 7.6 Hz, 2H), 7.65 (s, 1H), 7.52 (m, 1H), 7.46–7.42 (m, 2H), 6.39 (t, *J* = 6.8 Hz, 1H), 4.58 (m, 1H), 4.06–3.95 (m, 3H), 2.45 (m, 1H), 2.20–2.10 (m, 5H), 1.20–1.11 (m, 21H). ¹³C NMR (100.6 MHz, CDCl₃) δ 179.6, 159.7, 147.9, 137.2, 136.5, 132.4, 129.9, 128.1, 111.7, 87.1, 85.4, 72.1, 63.6, 41.4, 18.0, 13.5, 11.8. HRMS–ESI (*m/z*): [M+H]⁺ calcd for C₂₆H₄₀N₃O₅Si, 502.2732; found, 502.2734.

N-Benzoyl-5'-O-TIPS-5-methyl-2'-deoxycytidine Phosphoramidite



N-Benzoyl-5'-*O*-TIPS-5-methyl-2'-deoxycytidine Phosphoramidite was purified by flash chromatography on silica gel (Biotage Selekt, 100:0–80:20, hexane/EtOAc) (1.5 mmol scale; 840 mg, 1.08 mmol, 72% isolated yield). The ratio (2.2:1.8:1:1) of diastereomers was determined by ³¹P-NMR analysis. White amorphous solid. ¹H NMR (400 MHz, CDCl₃) δ 13.29 (brs, 1H), 8.33–8.30 (m, 2H), 7.69–7.31 (m, 9H), 6.39 (m, 0.34H), 6.15 (m, 0.66H), 5.02 (m, 1H), 4.66 (m, 0.34H), 4.40 (m, 0.66H), 4.20–3.51 (m, 5H), 2.84–2.72 (m, 2H), 2.54 (m, 0.34H), 2.38–2.07 (m, 4H), 1.90 (m, 0.66H), 1.28–0.96 (m, 33H). ¹³C NMR (100.6 MHz, CDCl₃) δ 179.6, 159.8, 159.7, 147.7, 147.7, 140.1, 140.1, 140.1, 140.0, 139.8, 137.2, 136.7, 136.6, 136.5, 132.3, 129.9, 128.7, 128.7, 128.7, 128.1, 126.1, 126.1, 126.1, 126.1, 126.0, 116.9, 116.8, 116.8, 111.6, 111.5, 87.1, 86.9, 86.9, 86.7, 86,6, 85.5, 85.4, 85.2, 73.8, 73.7, 73.6, 73.5, 73.3, 72.3, 72.2, 72.0, 71.9, 71.2, 71.2, 71.0, 71.0, 63.4, 63.3, 63.3, 63.1, 43.6, 43.6, 43.5, 43.4, 43.4, 43.2, 40.3, 40.3, 40.2, 40.1, 28.5, 28.4, 28.3, 28.3, 24.7, 24.6, 24.6, 24.5, 24.5, 24.1, 24.1, 24.0, 18.0, 18.0, 13.4, 11.9, 11.8 (only observed peaks). ³¹P NMR (162 MHz, CDCl₃)

δ 149.8, 149.8, 148.3, 147.9. **HRMS–ESI** (*m/z*): [M+H]⁺ calcd for C₄₁H₆₁N₅O₆PSi, 778.4123; found, 778.4122.

Phosphite (1b)



1b was purified by flash chromatography on silica gel (Biotage Selekt, 50:50:0–50:40:10, hexane/EtOAc/MeOH) (0.48 mmol scale; 300 mg, 0.31 mmol, 65% isolated yield). The ratio (1.1:1.1:1:1) of diastereomers was determined by ³¹P-NMR analysis. White amorphous solid. ¹H **NMR** (400 MHz, CDCl₃) δ 13.30 (brs, 1H), 8.33–8.30 (m, 3H), 7.61–7.28 (m, 10H), 6.35–6.22 (m, 2H), 5.43 (m, 1H), 5.21 (m, 1H), 4.86 (m, 1H), 4.18–3.56 (m, 6H), 2.94–2.75 (m, 2H), 2.48–1.78 (m, 13H), 1.25–1.06 (m, 21H). ¹³C **NMR** (100.6 MHz, CDCl₃) δ 170.4, 170.4, 170.4, 163.2, 163.2, 159.6, 150.1, 147.8, 147.8, 139.3, 139.2, 138.8, 138.7, 137.1, 136.2, 136.1, 136.1, 135.3, 135.1, 135.0, 132.4, 129.9, 129.4, 129.3, 129.2, 129.1, 128.1, 125.9, 125.8, 125.8, 116.7, 116.6, 116.6, 116.5, 111.9, 111.8, 111.5, 111.4, 111.4, 111.3, 86.6, 86.6, 86.2, 85.2, 85.1, 85.0, 84.7, 84.6, 84.5, 84.5, 83.3, 83.2, 83.2, 74.5, 74.2, 74.2, 74.1, 74.0, 73.3, 71.8, 71.6, 71.4, 71.0, 70.9, 70.7, 63.1, 63.0, 62.5, 62.5, 62.1, 40.3, 40.1, 37.3, 37.2, 37.1, 37.0, 28.1, 27.9, 20.9, 20.9, 18.0, 13.4, 12.6, 12.6, 11.8, 11.8 (only observed peaks). ³¹P **NMR** (162 MHz, CDCl₃) δ 139.9, 139.8, 139.7, 139.2. **HRMS–ESI** (*m*/*z*): [M+H]⁺ calcd for C₄₇H₆₂N₆O₁₂PSi, 961.3927; found, 961.3930.

Phosphite (1c)



1c was purified by flash chromatography on silica gel (Biotage Selekt, 98:2–80:20, DCM/EtOAc) (0.63 mmol scale; 267 mg, 0.26 mmol, 41% isolated yield). The ratio (1.3:1.2:1.1:1) of diasteromers was determined by ³¹P-NMR analysis. White amorphous solid. ¹H NMR (400 MHz, CDCl₃) δ 13.29 (brs, 1H), 8.32–8.30 (m, 2H), 8.07 (m, 1H), 7.59–7.51 (m, 2H), 7.46–7.20 (m, 8H), 6.31–6.16 (m, 2H), 5.39 (m, 1H), 4.85 (m, 1H), 4.38–3.54 (m, 7H), 2.92–2.74 (m, 2H), 2.46–1.74 (m, 10H), 1.18–1.07 (m, 21H), 0.90–0.88 (m, 9H), 0.09–0.08 (m, 6H). ¹³C NMR (100.6 MHz, CDCl₃) δ 179.5, 163.6, 159.6, 150.2, 150.1, 147.8, 139.4, 139.2, 138.9, 138.7, 137.1, 136.1, 135.8, 135.6, 132.4, 129.8, 129.3, 129.3, 129.2, 129.0, 128.1, 125.8, 125.7, 116.6, 116.6, 116.5, 116.4, 111.8, 111.8, 111.7, 111.0, 110.9, 110.9, 86.7, 86.6, 86.6, 86.6, 86.3, 86.3, 85.7, 85.7, 85.6, 85.6, 85.5, 85.4, 85.4, 85.2, 85.1, 85.0, 85.0, 84.9, 74.3, 74.1, 74.1, 73.9, 73.6, 73.5, 73.1, 73.0, 71.9, 71.6, 71.5, 71.4

71.3, 70.7, 70.6, 70.3, 70.3, 63.0, 63.0, 62.9, 62.4, 62.3, 62.1, 62.1, 61.8, 61.7, 61.6, 61.5, 40.4, 40.3, 40.2, 40.0, 28.2, 27.9, 27.8, 25.6, 18.0, 17.8, 13.4, 13.3, 12.6, 12.5, 11.8, 11.7, -4.7, -4.7, -4.7, -4.8 (only observed peaks). ³¹**P NMR** (162 MHz, CDCl₃) δ 139.7, 139.6, 139.4, 139.1. **HRMS–ESI** (*m/z*): [M+H]⁺ calcd for C₅₁H₇₄N₆O₁₁PSi₂, 1033.4686; found, 1033.4683.

Phosphite (1d)



1d was purified by flash chromatography on silica gel (Biotage Selekt, 50:50:0–50:40:10, hexane/EtOAc/MeOH) (0.8 mmol scale; 431 mg, 0.45 mmol, 56% isolated yield). The ratio (1.1:1.1:1:1) of diastereomers was determined by ³¹P-NMR analysis. White amorphous solid. ¹H NMR (400 MHz, CDCl₃) δ 13.25 (brs, 1H), 8.62 (m, 1H), 8.33–8.31 (m, 2H), 7.59–7.34 (m, 10H), 6.36–6.23 (m, 2H), 5.43 (m, 1H), 5.18 (m, 1H), 4.86 (m, 1H), 4.19–3.57 (m, 6H), 2.95–2.75 (m, 2H), 2.45–1.74 (m, 13H), 1.16–1.04 (m, 21H). ¹³C NMR (100.6 MHz, CDCl₃) δ 179.7, 179.7, 170.4, 170.4, 170.3, 163.4, 159.4, 159.4, 150.2, 150.1, 147.9, 139.2, 138.8, 138.8, 137.0, 136.3, 136.3, 136.2, 136.2, 136.1, 136.0, 135.0, 135.0, 134.9, 132.5, 129.9, 129.4, 129.4, 129.3, 129.2, 129.1, 129.1, 128.1, 126.0, 125.8, 125.8, 116.7, 116.6, 116.5, 112.4, 112.3, 112.2, 112.1, 111.1, 111.0, 111.0, 111.0, 86.3, 86.3, 86.0, 85.9, 85.2, 85.1, 85.0, 84.9, 84.5, 84.4, 84.4, 83.6, 83.5, 83.5, 83.4, 83.4, 74.4, 74.3, 74.2, 74.1, 74.1, 74.0, 73.8, 73.5, 73.4, 71.6, 71.6, 71.5, 71.0, 70.9, 70.9, 70.8, 63.1, 63.1, 63.0, 62.6, 62.5, 62.5, 62.4, 62.3, 62.2, 62.1, 62.0, 40.0, 39.8, 39.7, 39.7, 37.6, 37.5, 37.4, 37.3, 28.1, 27.9, 27.9, 20.9, 20.9, 18.0, 13.7, 12.3, 11.8, 11.8 (only observed peaks).³¹P NMR (162 MHz, CDCl₃) δ 140.3, 140.0, 139.7, 139.2. HRMS–ESI (*m*/*z*): [M+H]⁺ calcd for C₄₇H₆₂N₆O₁₂PSi, 961.3927; found, 961.3925.

N⁶-Benzoyl-5'-O-TIPS-2'-deoxyadenosine Phosphoramidite



*N*⁶-Benzoyl-5'-*O*-TIPS-2'-deoxyadenosine Phosphoramidite was purified by flash chromatography on silica gel (Biotage Selekt, 88:12–45:55, hexane/EtOAc) (3.33 mmol scale; 1.32 g, 1.67 mmol, 50% isolated yield). The ratio (2.3:2.3:1:1) of diastereomers was determined by ³¹P-NMR analysis. White amorphous solid. ¹H NMR (400 MHz, CDCl₃) δ 9.00 (m, 1H), 8.82 (m, 1H), 8.34 (s, 0.15H), 8.32 (s, 0.15H), 8.26 (s, 0.35H), 8.17 (s, 0.35H), 8.04–8.01 (m, 2H), 7.63–7.51 (m, 3H), 7.42–7.24 (m, 5H), 6.58 (m, 0.3H), 6.31 (m, 0.35H), 6.18 (m, 0.35H), 5.04 (m, 1H), 4.84 (m, 0.3H), 4.59 (m, 0.7H), 4.27 (m, 0.3H), 4.07–3.85 (m, 2H), 3.80–3.55 (m, 2.7H), 2.86–2.70 (m, 2.65H), 2.54 (m, 1H), 2.28 (m, 0.35H), 1.30–0.97 (m, 33H). ¹³C NMR (100.6 MHz, CDCl₃) δ 164.6, 152.6, 152.5, 152.5, 151.5, 151.5, 151.4, 151.4, 149.4, 149.4, 149.3, 141.5, 141.4, 141.3, 140.2, 140.2, 140.2,

139.9, 139.9, 139.9, 133.8, 133.7, 132.7, 128.8, 128.7, 128.6, 127.8, 126.1, 126.1, 126.0, 123.3, 123.2, 123.2, 123.2, 116.9, 116.8, 116.7, 87.4, 87.4, 87.4, 87.1, 87.0, 86.9, 84.6, 84.5, 84.5, 73.9, 73.7, 73.6, 73.5, 73.4, 73.3, 73.2, 73.1, 72.3, 72.1, 72.1, 71.9, 71.4, 71.3, 71.2, 71.1, 63.3, 63.3, 63.1, 53.4, 43.6, 43.5, 43.4, 43.3, 43.2, 43.2, 40.1, 40.0, 40.0, 39.9, 39.5, 39.5, 28.4, 28.4, 28.3, 24.7, 24.6, 24.6, 24.5, 24.5, 24.5, 24.2, 24.1, 24.1, 24.0, 17.9, 17.9, 11.8, 11.8 (only observed peaks). ³¹P NMR (162 MHz, CDCl₃) δ 150.3, 149.2, 148.4, 147.6. HRMS–ESI (*m*/*z*): [M+H]⁺ calcd for C₄₁H₅₉N₇O₅PSi, 788.4079; found, 788.4083.

Phosphite (1e)



1e was purified by flash chromatography on silica gel (Biotage Selekt, 50:50:0–50:40:10, hexane/EtOAc/MeOH) (1.67 mmol scale; 1.06 g, 1.09 mmol, 65% isolated yield). The ratio (1.4:1.4:1.2:1) of diastereomers was determined by ³¹P-NMR analysis. White amorphous solid. ¹H NMR (400 MHz, CDCl₃) δ 9.31–8.79 (m, 3H), 8.26 (m, 1H), 8.06–8.04 (m, 2H), 7.63–7.50 (m, 3H), 7.43–7.31 (m, 6H), 6.47–6.22 (m, 2H), 5.52–4.93 (m, 3H), 4.28–4.08 (m, 3H), 4.04–3.61 (m, 3H), 2.96–2.60 (m, 4H), 2.49–2.05 (m, 5H), 1.95–1.87 (m, 3H), 1.14–1.02 (m, 21H). ¹³C NMR (100.6 MHz, CDCl₃) δ 170.6, 170.5, 170.4, 170.4, 164.8, 163.4, 152.5, 151.6, 150.2, 149.6, 141.6, 141.5, 141.2, 141.0, 139.2, 139.2, 138.9, 138.8, 136.2, 135.2, 135.1, 135.0, 133.6, 132.7, 129.4, 129.4, 129.3, 129.1, 128.9, 128.8, 128.0, 125.8, 125.7, 125.5, 123.4, 123.4, 116.7, 116.6, 116.6, 116.5, 111.5, 111.4, 111.4, 86.9, 86.9, 86.8, 86.8, 85.9, 85.0, 84.8, 84.7, 84.6, 84.6, 84.3, 83.5, 83.5, 83.4, 83.4, 83.3, 83.3, 74.7, 74.4, 74.3, 74.3, 74.2, 74.2, 74.1, 73.9, 73.7, 71.8, 71.6, 71.5, 71.3, 71.2, 70.2, 63.0, 62.9, 62.9, 62.6, 62.5, 62.4, 62.3, 62.2, 62.2, 40.0, 40.0, 39.4, 39.1, 39.1, 37.3, 37.2, 37.2, 37.0, 28.2, 28.1, 28.0, 28.0, 21.0, 20.9, 20.9, 18.0, 18.0, 12.6, 12.6, 12.5, 11.8, 11.8 (only observed peaks). ³¹P NMR (162 MHz, CDCl₃) δ 140.8, 140.0, 139.8, 139.0. HRMS–ESI (*m*/*z*): [M+H]⁺ calcd for C₄₇H₆₀N₈O₁₁PSi, 971.3883; found, 971.3892.

N²-Isobutyryl-O⁶-(diphenylcarbamoyl)-5'-O-TIPS-2'-deoxyguanosine



*N*²-Isobutyryl-*O*⁶-(diphenylcarbamoyl)-5'-*O*-TIPS-2'-deoxyguanosine was prepared according to the reported procedure¹⁰ and purified by flash chromatography on silica gel (Biotage Selekt, 90:10–67:33, DCM/EtOAc) (2.84 mmol scale; 1.39 g, 2.02 mmol, 71% isolated yield). White solid. **M.p.** 123–127 °C. ¹**H NMR** (400 MHz, CDCl₃) δ 8.27 (m, 1H), 8.03 (m, 1H), 7.44–7.34 (m, 8H), 7.26–7.23 (m, 2H), 6.63 (m, 1H), 4.80 (m, 1H), 4.14 (m, 1H), 3.99–3.91 (m, 2H), 2.85 (brs, 1H),

2.67–2.59 (m, 2H), 1.64 (m, 1H), 1.26 (d, J = 6.8 Hz, 6H), 1.18–1.05 (m, 21H). ¹³C NMR (100.6 MHz, CDCl₃) δ 175.3, 155.8, 154.7, 151.5, 150.4, 142.8, 141.7, 129.1, 127.1, 121.3, 88.2, 84.6, 72.4, 64.2, 41.7, 36.3, 19.3, 18.0, 11.9. **HRMS–ESI** (*m*/*z*): [M+H]⁺ calcd for C₃₆H₄₉N₆O₆Si, 689.3477; found, 689.3475.

N²-Isobutyryl-O⁶-(diphenylcarbamoyl)-5'-O-TIPS-2'-deoxyguanosine Phosphoramidite



*N*²-Isobutyryl-*O*⁶-(diphenylcarbamoyl)-5'-*O*-TIPS-2'-deoxyguanosine Phosphoramidite was purified by flash chromatography on silica gel (Biotage Selekt, 93:7–66:34, hexane/EtOAc) (1 mmol scale; 676 mg, 0.7 mmol, 70% isolated yield). The ratio (2.1:1.9:1:1) of diastereomers was determined by ³¹P-NMR analysis. White amorphous solid. ¹H NMR (400 MHz, CDCl₃) δ 8.18 (m, 1H), 7.94 (m, 1H), 7.43–7.22 (m, 15H), 6.47 (m, 0.34H), 6.16 (m, 0.66H), 5.03 (m, 1H), 4.80 (m, 0.34H), 4.54 (m, 0.66H), 4.23 (m, 0.34H), 4.02–3.57 (m, 4.66H), 3.07 (m, 1H), 2.88–2.29 (m, 4H), 1.29–0.97 (m, 39H). ¹³C NMR (100.6 MHz, CDCl₃) δ 175.9, 175.5, 156.0, 155.9, 155.9, 154.5, 154.4, 154.4, 151.9, 151.9, 151.8, 150.4, 150.3, 142.3, 142.2, 142.2, 141.7, 140.1, 139.9, 129.0, 128.6, 128.6, 128.5, 126.8, 126.1, 126.1, 126.0, 126.0, 121.3, 121.2, 121.1, 116.9, 116.8, 116.7, 87.4, 87.4, 87.2, 87.1, 87.0, 87.0, 86.9, 84.5, 84.3, 73.9, 73.7, 73.5, 73.4, 73.3, 73.2, 73.1, 72.9, 72.0, 72.0, 71.8, 71.8, 71.3, 71.2, 71.1, 71.0, 63.4, 63.0, 43.6, 43.5, 43.4, 43.3, 43.3, 43.2, 43.1, 40.2, 40.0, 39.6, 39.6, 35.6, 35.3, 28.4, 28.4, 28.3, 28.2, 24.6, 24.6, 24.5, 24.4, 24.1, 24.0, 24.0, 19.2, 19.1, 17.9, 11.8, 11.8 (only observed peaks). ³¹P NMR (162 MHz, CDCl₃) *δ* 150.1, 149.2, 148.6, 147.7. HRMS–ESI (*m*/*z*): [M+H]⁺ calcd for C₅₁H₇₀N₈O₇PSi, 965.4869; found, 965.4866.

Phosphite (1f)



1f was purified by flash chromatography on silica gel (Biotage Selekt, 50:50:0–50:40:10, hexane/EtOAc/MeOH) (0.6 mmol scale; 641 mg, 0.56 mmol, 93% isolated yield). The ratio (1.2:1.1:1) of diastereomers was determined by ³¹P-NMR analysis. White amorphous solid. ¹H NMR (400 MHz, CDCl₃) δ 8.83 (m, 1H), 8.29 (m, 1H), 8.16 (m, 1H), 7.50–7.24 (m, 16H), 6.35–6.24 (m, 2H), 5.50–4.93 (m, 3H), 4.25–3.59 (m, 6H), 2.94–2.57 (m, 4H), 2.50–2.29 (m, 2H), 2.24–2.04 (m, 4H), 1.97–1.88 (m, 3H), 1.26–1.24 (m, 6H), 1.09–1.00 (m, 21H). ¹³C NMR (100.6 MHz, CDCl₃) δ 175.4, 175.3, 170.6, 170.5, 170.4, 170.4, 163.5, 156.0, 154.5, 152.0, 151.9, 150.4, 150.2, 142.5, 142.3, 142.2, 141.7, 139.2, 139.0, 138.8, 136.2, 135.4, 135.3, 135.3, 129.3, 129.3, 129.2, 129.1, 129.0,

127.1, 125.9, 125.8, 121.4, 121.4, 121.3, 116.6, 116.6, 116.5, 111.4, 111.3, 111.3, 111.3, 86.9, 86.8, 86.6, 85.8, 85.0, 84.9, 84.9, 84.7, 84.6, 84.5, 84.4, 84.3, 84.2, 83.6, 83.5, 83.3, 83.3, 74.7, 74.4, 74.3, 74.3, 74.2, 74.1, 73.6, 71.7, 71.5, 71.3, 71.0, 70.8, 70.7, 63.2, 63.0, 62.5, 62.5, 62.3, 62.1, 40.0, 39.9, 39.5, 39.4, 37.3, 37.2, 37.1, 37.0, 36.0, 28.1, 27.9, 21.0, 20.9, 19.3, 17.9, 12.6, 12.5, 11.8, 11.8 (only observed peaks). ³¹P NMR (162 MHz, CDCl₃) δ 141.0, 140.5, 139.8, 139.1. HRMS–ESI (*m*/*z*): [M+H]⁺ calcd for C₅₇H₇₁N₉O₁₃PSi, 1148.4673; found, 1148.4672.

5. General Procedure for Synthesis of tert-Alkylphosphonate Oligonucleotides

The reaction in Table 2, entry 2 is representative. In a glovebox, to an oven-dried vial with a stirring bar was added PTH2 (13.2 mg, 0.05 mmol), phosphite 1a-1 (42.9 mg, 0.05 mmol), redox-active ester 2a (46.4 mg, 0.15 mmol) and LiBF₄ (4.7 mg, 0.05 mmol). Then, MeCN (300 μ L) and DCM (200 μ L) were added to the reaction mixture. After sealing the vial with parafilm, the reaction mixture was stirred and irradiated with a 34W blue LED with UC reactor to keep the temperature at 10 °C (Supplementary Fig. 2). After 18 h, the solvents were removed under reduced pressure. The crude material was then purified by flash column chromatography on silica gel (80:20:0–50:45:5, hexane/EtOAc/MeOH) to give the alkylated product 3aa (29.6 mg, 0.035 mmol, 70% isolated yield) as a white amorphous solid.



Supplementary Fig. 2. Light set up

6. Characterization Data for Alkylated Products

tert-Alkylphosphonate 3aa



The product **3aa** was purified by flash chromatography on silica gel (80:20:0–50:45:5, hexane/EtOAc/MeOH) (Table 2, entry 2; 29.6 mg, 0.035 mmol, 70% isolated yield). The ratio (before isolation: 1.2:1→after isolation: 1:1) of diastereomers was determined by ³¹P-NMR analysis. White amorphous solid. ¹H NMR (400 MHz, CDCl₃) δ 9.07–8.98 (m, 2H), 7.55–7.23 (m, 7H), 6.29–6.24 (m, 2H), 5.14 (m, 1H), 4.86 (t, J = 5.8 Hz, 0.5H), 4.60 (t, J = 6.0 Hz, 0.5H), 4.26–4.11 (m, 3.5H), 3.87 (m, 1H), 3.71 (m, 1H), 3.39 (m, 0.5H), 2.45–2.34 (m, 1.5H), 2.10–1.85 (m, 11.5H), 1.70–1.65 (m, 6H), 1.10–1.03 (m, 21H). ¹³C NMR (100.6 MHz, CDCl₃) δ 170.5, 170.3, 163.6, 163.5, 150.3, 140.2, 140.0, 139.9, 135.1, 134.8, 134.6, 128.4, 128.4, 128.4, 127.7, 127.7, 127.6, 127.5, 127.4, 127.4, 111.6, 111.5, 111.2, 86.8, 86.8, 85.6, 85.6, 84.7, 84.7, 84.3, 83.0, 82.9, 82.8, 82.7, 78.5, 78.5, 78.4, 78.3, 73.9, 73.9, 65.6, 65.5, 64.8, 64.8, 63.2, 40.1, 40.1, 39.9, 39.0, 38.9, 38.8, 38.7, 37.2, 37.2, 24.5, 24.5, 24.1, 24.1, 23.7, 23.7, 23.5, 23.5, 20.8, 18.0, 18.0, 18.0, 12.6, 12.3, 12.3, 12.2, 11.7, 11.7 (only observed peaks). ³¹P NMR (162 MHz, CDCl₃) δ 34.6, 33.5. HRMS–ESI (*m*/*z*): [M+H]⁺ calcd for C₄₀H₆₀N₄O₁₂PSi, 847.3709; found, 847.3710.

The separation of the diastereomers of 3aa.

The crude residue of **3aa** (from 20×0.05 mmol scale) was purified with column chromatography (silica gel, hexane/EtOAc/MeOH = 50:50:0 to 42.5:42.5:15), and then the fractions containing the diastereomers mixture were collected and further purified by preparative HPLC (Reverse phase, C18 column, 10mM NH₄HCO₃ aq./MeCN = 30/70 to 15/85) to obtain 200 mg (0.24 mmol) of (*R*_P)-**3aa** and 250 mg (0.30 mmol) of (*S*_P)-**3aa**.

50 mg of the single diastereomer [identified as (R_P) -3aa] was weighed out and transferred to a clean glass tube. About 1 mL of acetonitrile was added to the tube and the mixture was heated until the solid dissolved completely. To the solution was added water (2~3 mL) quietly and the solution was allowed to cool slowly to room temperature. The solution was then placed in the fridge to further promote crystal formation. The crystals were collected using a filtration apparatus and washed with a small amount of water. The crystals were then dried in vacuo.

tert-Alkylphosphonate 3ba



The product **3ba** was purified by flash chromatography on silica gel (80:20:0–50:45:5, hexane/EtOAc/MeOH) (Figure 2; 24.7 mg, 0.026 mmol, 52% isolated yield). The ratio (before isolation: 1.2:1) of diastereomers was determined by ³¹P-NMR analysis. The diastereomers **3ba-d1** and **3ba-d2** were separated and data were measured respectively.

3ba-d1

White amorphous solid. ¹H NMR (400 MHz, CDCl₃) δ 13.29 (brs, 1H), 8.32–8.30 (m, 2H), 8.15 (brs, 1H), 7.56–7.51 (m, 4H), 7.46–7.42 (m, 2H), 7.36–7.32 (m, 2H), 7.27–7.24 (m, 2H), 6.30–6.24 (m, 2H), 5.14 (m, 1H), 4.61 (t, *J* = 6.0 Hz, 1H), 4.25 (m, 1H), 4.15–4.13 (m, 2H), 4.07 (m, 1H), 3.92–3.86 (m, 2H), 2.37 (m, 1H), 2.17 (m, 1H), 2.10–2.07 (m, 6H), 1.99 (d, *J* = 1.2 Hz, 3H), 1.93–1.84 (m, 2H), 1.70–1.65 (m, 6H), 1.14–1.03 (m, 21H). ¹³C NMR (100.6 MHz, CDCl₃) δ 170.3, 163.0, 159.6, 149.9, 147.8, 140.0, 139.9, 137.1, 136.0, 134.6, 132.5, 129.9, 128.5, 128.5, 128.1, 127.6, 127.6, 127.5, 112.0, 111.6, 87.2, 85.0, 84.8, 82.8, 82.8, 78.6, 78.5, 73.9, 64.9, 64.8, 63.3, 40.1, 39.4, 39.3, 38.8, 37.2, 24.2, 24.1, 23.7, 23.7, 20.9, 18.0, 18.0, 13.4, 12.6, 11.8 (only observed peaks). ³¹P NMR (162 MHz, CDCl₃) δ 34.7. HRMS–ESI (*m*/*z*): [M+H]⁺ calcd for C₄₇H₆₅N₅O₁₂PSi, 950.4131; found, 950.4128.

3ba-d2

White amorphous solid. ¹H NMR (400 MHz, CDCl₃) δ 13.29 (brs, 1H), 8.32–8.29 (m, 2H), 8.13 (m, 1H), 7.57–7.42 (m, 7H), 7.37–7.34 (m, 2H), 7.28 (m, 1H), 6.29–6.22 (m, 2H), 5.14 (m, 1H), 4.89 (t, *J* = 6.4 Hz, 1H), 4.25–4.08 (m, 3H), 3.75–3.72 (m, 2H), 3.41 (m, 1H), 2.53 (dd, *J* = 13.6, 4.8 Hz, 1H), 2.38 (m, 1H), 2.10–2.03 (m, 7H), 1.99 (d, *J* = 1.2 Hz, 3H), 1.85 (m, 1H), 1.69–1.64 (m, 6H), 1.13–1.04 (m, 21H). ¹³C NMR (100.6 MHz, CDCl₃) δ 170.5, 163.2, 159.6, 149.9, 147.9, 140.2, 137.1, 136.0, 135.1, 132.5, 129.9, 128.4, 128.4, 128.1, 127.7, 127.7, 127.4, 127.4, 112.0, 111.5, 86.0, 85.9, 84.9, 84.8, 83.0, 83.0, 78.5, 78.4, 73.8, 65.5, 65.4, 63.3, 40.3, 40.3, 40.1, 38.8, 37.2, 24.5, 24.5, 23.6, 23.5, 20.9, 18.0, 13.4, 12.3, 11.7 (only observed peaks). ³¹P NMR (162 MHz, CDCl₃) δ 33.6. HRMS–ESI (*m*/*z*): [M+H]⁺ calcd for C₄₇H₆₅N₅O₁₂PSi, 950.4131; found, 950.4131.

tert-Alkylphosphonate 3ca



The product **3ca** was purified by flash chromatography on silica gel (80:20:0–50:45:5, hexane/EtOAc/MeOH) (Figure 2; 25.6 mg, 0.025 mmol, 50% isolated yield). The ratio (before isolation: 1.1:1→after isolation: 1.3:1) of diastereomers was determined by ³¹P-NMR analysis. White amorphous solid. ¹H NMR (400 MHz, CDCl₃) δ 13.30 (brs, 1H), 8.37–8.30 (m, 3H), 7.58–7.22 (m, 10H), 6.30–6.17 (m, 2H), 4.88 (t, J = 6.0 Hz, 0.43H), 4.63 (t, J = 6.0 Hz, 0.57H), 4.24 (m, 1H), 4.12–3.88 (m, 4.57H), 3.76 (m, 1H), 3.49 (m, 0.43H), 2.50 (m, 0.43H), 2.22–1.77 (m, 9.57H), 1.70–1.64 (m, 6H), 1.11–1.05 (m, 21H), 0.89 (s, 9H), 0.08–0.07 (m, 6H). ¹³C NMR (100.6 MHz, CDCl₃) δ 179.6, 163.4, 163.3, 159.6, 149.9, 147.8, 140.4, 140.1, 140.0, 137.1, 136.0, 135.7, 135.1, 132.5, 129.9, 128.4, 128.4, 128.4, 128.1, 127.8, 127.7, 127.6, 127.5, 127.4, 127.3, 112.0, 111.0, 111.2, 111.1, 87.2, 86.1, 85.4, 85.3, 85.3, 85.1, 85.0, 78.3, 78.3, 78.0, 77.9, 71.8, 71.6, 65.5, 65.4, 64.4, 64.3, 63.3, 63.2, 40.6, 40.5, 40.3, 40.2, 40.1, 39.4, 39.3, 38.8, 38.7, 25.7, 24.2, 24.1, 24.0, 23.8, 23.6, 18.0, 18.0, 18.0, 17.9, 13.4, 13.4, 12.6, 12.3, 11.8, 11.7, -4.7, -4.8, -4.9 (only observed peaks). ³¹P NMR (162

MHz, CDCl₃) δ 34.7, 33.2. **HRMS–ESI** (*m/z*): [M+H]⁺ calcd for C₅₁H₇₇N₅O₁₁PSi₂, 1022.4890; found, 1022.4885.

tert-Alkylphosphonate 3da



The product **3da** was purified by flash chromatography on silica gel (80:20:0–50:45:5, hexane/EtOAc/MeOH) (Figure 2; 21.9 mg, 0.023 mmol, 46% isolated yield). The ratio (before isolation: 1.1:1→after isolation: 1:1) of diastereomers was determined by ³¹P-NMR analysis. White amorphous solid. ¹H NMR (400 MHz, CDCl₃) δ 13.29 (brs, 1H), 8.42–8.32 (m, 3H), 7.72–7.25 (m, 10H), 6.30–6.24 (m, 2H), 5.14 (m, 1H), 4.89 (t, J = 6.0 Hz, 0.5H), 4.66 (t, J = 6.0 Hz, 0.5H), 4.28–4.08 (m, 3.5H), 3.88 (m, 1H), 3.72 (m, 1H), 3.42 (m, 0.5H), 2.47–2.42 (m, 1.5H), 2.18–2.17 (m, 3H), 2.12–2.04 (m, 4H), 1.91–1.81 (m, 4.5H), 1.71–1.65 (m, 6H), 1.10–1.04 (m, 21H). ¹³C NMR (100.6 MHz, CDCl₃) δ 179.7, 170.5, 170.3, 163.3, 159.6, 159.4, 150.1, 147.8, 140.2, 140.2, 140.0, 139.9, 137.1, 137.0, 136.3, 135.6, 134.8, 134.8, 132.6, 132.5, 129.9, 128.5, 128.4, 128.1, 128.1, 127.7, 127.7, 127.6, 127.5, 127.4, 112.5, 112.4, 111.2, 86.9, 85.7, 85.6, 85.3, 85.2, 84.4, 84.3, 83.3, 83.2, 83.1, 83.0, 78.5, 78.4, 78.3, 73.9, 65.4, 65.4, 64.8, 64.7, 63.3, 40.1, 40.1, 39.9, 39.1, 39.0, 38.8, 38.8, 37.5, 37.5, 24.5, 24.1, 24.1, 23.7, 23.6, 20.8, 18.0, 18.0, 13.7, 13.4, 12.3, 12.2, 11.8, 11.7 (only observed peaks). ³¹P NMR (162 MHz, CDCl₃) δ 34.7, 33.7. HRMS–ESI (*m*/*z*): [M+H]⁺ calcd for C₄₇H₆₅N₅O₁₂PSi, 950.4131; found, 950.4133.

tert-Alkylphosphonate 3ea



The product **3ea** was purified by flash chromatography on silica gel (50:50:0–50:42:8, hexane/EtOAc/MeOH) (Figure 2; 15.8 mg, 0.017 mmol, 33% isolated yield). The ratio (before isolation: 1.1:1) of diasteromers was determined by ³¹P-NMR analysis. The diastereomers **3ea-d1** and **3ea-d2** were separated and data were measured respectively.

3ea-d1

White amorphous solid. ¹**H NMR** (400 MHz, CDCl₃) δ 9.08 (brs, 1H), 8.81 (s, 1H), 8.69 (brs, 1H), 8.28 (s, 1H), 8.03 (d, *J* = 7.2 Hz, 2H), 7.62–7.28 (m, 9H), 6.51 (m, 1H), 6.18 (m, 1H), 5.12–5.08 (m, 2H), 4.24–4.12 (m, 3H), 3.94 (s, 1H), 3.79 (m, 1H), 3.50 (m, 1H), 2.81–2.71 (m, 2H), 2.32 (m, 1H),

2.07 (s, 3H), 1.99 (s, 3H), 1.80–1.68 (m, 7H), 1.12–1.03 (m, 21H). ¹³C NMR (100.6 MHz, CDCl₃) δ 170.5, 163.3, 150.0, 140.4, 140.3, 135.3, 133.6, 132.8, 132.8, 128.8, 128.5, 128.5, 128.0, 127.7, 127.6, 127.4, 127.4, 111.5, 86.4, 86.4, 85.2, 84.3, 83.2, 83.2, 78.6, 78.6, 74.0, 63.3, 40.2, 37.0, 29.7, 29.6, 24.6, 24.5, 23.7, 23.6, 20.9, 18.0, 12.4, 11.8 (only observed peaks). ³¹P NMR (162 MHz, CDCl₃) δ 33.8. HRMS–ESI (*m/z*): [M+H]⁺ calcd for C₄₇H₆₃N₇O₁₁PSi, 960.4087; found, 960.4096.

3ea-d2

White amorphous solid. ¹**H** NMR (400 MHz, CDCl₃) δ 9.00 (brs, 1H), 8.82 (s, 1H), 8.25 (brs, 1H), 8.21 (s, 1H), 8.03 (d, J = 7.2 Hz, 2H), 7.64–7.51 (m, 5H), 7.37–7.33 (m, 2H), 7.28–7.22 (m, 2H), 6.37 (m, 1H), 6.27 (m, 1H), 5.16 (m, 1H), 4.87 (t, J = 6.0 Hz, 1H), 4.33–4.24 (m, 2H), 4.17–4.11 (m, 2H), 3.93–3.84 (m, 2H), 2.55 (m, 1H), 2.39 (m, 1H), 2.21 (m, 1H), 2.11 (s, 3H), 2.00–1.91 (m, 4H), 1.73–1.69 (m, 6H), 1.14–1.02 (m, 21H). ¹³C NMR (100.6 MHz, CDCl₃) δ 170.3, 163.1, 149.9, 141.1, 134.7, 132.8, 128.9, 128.5, 127.9, 127.6, 127.6, 127.5, 111.6, 87.2, 84.9, 84.2, 82.9, 82.8, 78.6, 78.5, 73.9, 64.9, 63.2, 40.1, 39.2, 39.2, 38.8, 37.2, 24.3, 24.3, 23.7, 23.6, 20.9, 18.0, 12.7, 11.8 (only observed peaks). ³¹P NMR (162 MHz, CDCl₃) δ 34.3. HRMS–ESI (m/z): [M+H]⁺ calcd for C₄₇H₆₃N₇O₁₁PSi, 960.4087; found, 960.4088.

tert-Alkylphosphonate 3fa



The product **3fa** (from total 0.45 mmol scale synthesis) was purified with column chromatography (silica gel, hexane/EtOAc/MeOH = 50:50:0 to 50:40:10), and then the fractions containing the product were collected and further purified by preparative HPLC (30:70-0:100, 10mM NH₄HCO₃ in H₂O/MeCN) (Figure 2; 25.6 mg, 0.023 mmol, 5% isolated yield). The ratio (before isolation: 1.1:1) of diasteromers was determined by ³¹P-NMR analysis. The diastereomers **3fa-d1** and **3fa-d2** were separated and data were measured respectively.

3fa-d1

Off-white amorphous solid. ¹H NMR (400 MHz, CDCl₃) δ 8.36–8.26 (m, 2H), 8.12 (s, 1H), 7.59–7.21 (m, 16H), 6.29–6.25 (m, 2H), 5.18 (m, 1H), 4.86 (t, *J* = 6.0 Hz, 1H), 4.32–4.12 (m, 4H), 3.90–3.82 (m, 2H), 2.38 (m, 1H), 2.20–2.08 (m, 6H), 2.01–1.95 (m, 4H), 1.72–1.68 (m, 6H), 1.27 (d, *J* = 6.8 Hz, 6H), 1.05–1.00 (m, 21H). ¹³C NMR (100.6 MHz, CDCl₃) δ 170.3, 163.3, 156.0, 154.6, 152.1, 150.4, 150.0, 142.0, 140.1, 140.0, 134.8, 129.1, 128.5, 128.4, 127.6, 127.6, 127.5, 126.8, 121.2, 111.5, 87.3, 84.7, 83.9, 82.7, 82.7, 78.5, 78.4, 73.8, 64.9, 64.8, 63.2, 40.1, 39.3, 39.3, 38.8, 37.2, 36.0, 24.3, 24.3, 23.6, 23.6, 20.9, 19.3, 18.0, 18.0, 12.7, 11.8 (only observed peaks). ³¹P NMR (162 MHz, CDCl₃) δ 34.6. HRMS–ESI (*m*/*z*): [M+H]⁺ calcd for C₅₇H₇₄N₈O₁₃PSi, 1137.4877; found, 1137.4885.

3fa-d2

Off-white amorphous solid. ¹H NMR (400 MHz, CDCl₃) δ 8.41–8.24 (m, 2H), 8.17 (s, 1H), 7.58– 7.24 (m, 16H), 6.42 (m, 1H), 6.16 (dd J = 8.8, 5.2 Hz, 1H), 5.13 (m, 1H), 5.03 (m, 1H), 4.26–4.12 (m, 3H), 3.89 (m, 1H), 3.74 (m, 1H), 3.49 (m, 1H), 2.77–2.67 (m, 2H), 2.31 (m, 1H), 2.12–2.06 (m, 4H), 2.00–1.99 (m, 3H), 1.81 (m, 1H), 1.71–1.67 (m, 6H), 1.25 (d, J = 6.8 Hz, 6H), 1.05–1.02 (m, 21H). ¹³C NMR (100.6 MHz, CDCl₃) δ 170.5, 163.4, 156.0, 154.6, 152.1, 150.4, 149.9, 142.1, 141.8, 140.4, 135.5, 129.2, 128.4, 128.4, 127.7, 127.6, 127.4, 121.3, 111.4, 86.3, 86.3, 85.2, 84.2, 83.1, 83.0, 78.6, 78.6, 73.9, 65.6, 65.5, 63.3, 40.2, 38.9, 37.0, 24.5, 24.5, 23.7, 23.6, 20.8, 19.3, 19.3, 18.0, 12.3, 11.8 (only observed peaks). ³¹P NMR (162 MHz, CDCl₃) δ 33.5. HRMS–ESI (*m*/*z*): [M+H]⁺ calcd for C₅₇H₇₄N₈O₁₃PSi, 1137.4877; found, 1137.4891.

tert-Alkylphosphonate 3ab



The product **3ab** was purified by flash chromatography on silica gel (80:20:0–50:45:5, hexane/EtOAc/MeOH) (Figure 2; 26.9 mg, 0.029 mmol, 58% isolated yield). The ratio (before isolation: 1.2:1→after isolation: 1:1) of diasteromers was determined by ³¹P-NMR analysis. White amorphous solid. ¹H NMR (400 MHz, CDCl₃) δ 8.93–8.86 (m, 2H), 7.49–7.24 (m, 6H), 6.29–6.24 (m, 2H), 5.15 (m, 1H), 4.86 (t, J = 6.0 Hz, 0.5H), 4.57 (t, J = 5.8 Hz, 0.5H), 4.28–4.09 (m, 3.5H), 3.91–3.72 (m, 2H), 3.38 (m, 0.5H), 2.47–2.38 (m, 1.5H), 2.11–1.88 (m, 11.5H), 1.66–1.61 (m, 6H), 1.15–1.00 (m, 21H). ¹³C NMR (100.6 MHz, CDCl₃) δ 170.7, 170.5, 170.3, 163.6, 163.5, 150.5, 150.3, 150.2, 139.4, 139.1, 139.1, 136.1, 135.1, 134.8, 134.7, 134.6, 131.5, 131.5, 131.4, 129.6, 129.5, 129.5, 129.4, 121.8, 121.7, 121.7, 121.6, 111.7, 111.6, 111.4, 111.3, 111.3, 86.9, 85.9, 85.6, 85.6, 85.0, 84.9, 84.3, 84.3, 82.9, 82.9, 82.7, 82.7, 78.8, 78.7, 78.5, 78.4, 74.7, 73.7, 65.8, 65.7, 64.9, 64.9, 63.2, 62.6, 40.0, 39.9, 39.0, 38.7, 38.6, 37.2, 24.5, 24.4, 24.1, 24.1, 23.5, 23.5, 23.4, 21.0, 20.8, 18.0, 12.6, 12.6, 12.4, 12.3, 11.8, 11.7 (only observed peaks). ³¹P NMR (162 MHz, CDCl₃) δ 33.7, 32.7. HRMS–ESI (*m*/*z*): [M+H]⁺ calcd for C₄₀H₅₉BrN₄O₁₂PSi, 925.2814; found, 925.2816.

tert-Alkylphosphonate 3ac



The product **3ac** was purified by flash chromatography on silica gel (80:20:0–50:45:5, hexane/EtOAc/MeOH) (Figure 2; 26.6 mg, 0.031 mmol, 62% isolated yield). The ratio (crude 1.1:1

→isolated 1.1:1) of diasteromers was determined by ³¹P-NMR analysis. White amorphous solid. ¹H NMR (400 MHz, CDCl₃) δ 8.94–8.82 (m, 2H), 7.49–7.16 (m, 7H), 6.32–6.23 (m, 2H), 5.18 (m, 1H), 4.95 (t, *J* = 5.8 Hz, 0.48H), 4.69 (t, *J* = 6.0 Hz, 0.52H), 4.33–4.08 (m, 3.52H), 3.91–3.79 (m, 2H), 3.62 (m, 0.48H), 2.95–2.88 (m, 2H), 2.68–2.56 (m, 2H), 2.50–2.23 (m, 3H), 2.11–1.89 (m, 12H), 1.15–1.03 (m, 21H). ¹³C NMR (100.6 MHz, CDCl₃) δ 170.4, 170.4, 163.5, 163.4, 150.2, 141.6, 141.6, 141.5, 141.5, 135.1, 134.8, 134.8, 134.5, 128.3, 128.2, 128.2, 127.5, 127.5, 127.5, 127.5, 127.0, 126.9, 111.8, 111.6, 111.2, 111.2, 86.7, 85.8, 85.7, 84.7, 84.6, 84.4, 84.3, 83.0, 82.9, 82.7, 82.7, 78.3, 78.2, 78.2, 73.7, 73.7, 65.8, 65.8, 65.1, 65.1, 63.4, 63.2, 45.7, 45.6, 44.3, 44.2, 39.8, 39.3, 39.3, 37.2, 37.1, 30.9, 30.8, 30.5, 30.5, 30.4, 29.7, 20.9, 18.0, 18.0, 17.2, 17.2, 12.6, 12.3, 12.3, 11.7 (only observed peaks). ³¹P NMR (162 MHz, CDCl₃) δ 31.9, 30.8. HRMS–ESI (*m*/*z*): [M+H]⁺ calcd for C₄₁H₆₀N₄O₁₂PSi, 859.3709; found, 859.3714.

tert-Alkylphosphonate 3ad



The product **3ad** was purified by flash chromatography on silica gel (80:20:0–50:45:5, hexane/EtOAc/MeOH) (Figure 2; 14.8 mg, 0.017 mmol, 34% isolated yield). The ratio (before isolation: 1.2:1→after isolation: 1.2:1) of diasteromers was determined by ³¹P-NMR analysis. White amorphous solid.¹H NMR (400 MHz, CDCl₃) δ 8.63–8.51 (m, 2H), 7.49–7.15 (m, 7H), 6.28–6.20 (m, 2H), 5.12 (m, 1H), 4.90 (t, J = 5.6 Hz, 0.45H), 4.65 (t, J = 5.8 Hz, 0.55H), 4.24–4.04 (m, 3.55H), 3.88–3.76 (m, 2H), 3.56 (m, 0.45H), 2.46–1.83 (m, 21H), 1.14–1.03 (m, 21H). ¹³C NMR (100.6 MHz, CDCl₃) δ 170.4, 170.3, 163.4, 150.1, 139.3, 135.2, 134.8, 134.6, 128.5, 128.5, 128.3, 127.3, 111.7, 111.5, 111.2, 86.7, 85.7, 84.8, 84.6, 84.3, 82.7, 78.2, 78.1, 73.8, 73.7, 65.6, 65.0, 64.9, 63.4, 63.3, 51.9, 51.9, 50.5, 39.8, 39.2, 39.2, 37.1, 35.1, 35.0, 34.2, 34.1, 24.2, 24.2, 20.9, 18.0, 18.0, 18.0, 12.6, 12.3, 12.3, 11.8 (only observed peaks). ³¹P NMR (162 MHz, CDCl₃) δ 34.2, 33.1. HRMS–ESI (m/z): [M+H]⁺ calcd for C₄₂H₆₂N₄O₁₂PSi, 873.3866; found, 873.3863.

tert-Alkylphosphonate 3ae



The product **3ae** was purified by flash chromatography on silica gel (80:20:0-50:45:5, hexane/EtOAc/MeOH) (Figure 2; 22.7 mg, 0.026 mmol, 51% isolated yield). The ratio (crude 1.2:1 \rightarrow isolated 1.2:1) of diasteromers was determined by ³¹P-NMR analysis. White amorphous solid. ¹H

NMR (400 MHz, CDCl₃) δ 8.69–8.51 (m, 2H), 7.48–7.22 (m, 7H), 6.28–6.20 (m, 2H), 5.16 (m, 1H), 4.84 (t, J = 6.0 Hz, 0.43H), 4.45 (t, J = 5.6 Hz, 0.57H), 4.26–4.05 (m, 3.57H), 3.86–3.74 (m, 4H), 3.54–3.50 (m, 1.43H), 3.40 (m, 1H), 2.46–2.34 (m, 5H), 2.11–1.80 (m, 12H), 1.13–1.02 (m, 21H). ¹³C NMR (100.6 MHz, CDCl₃) δ 170.4, 170.4, 163.4, 163.3, 163.2, 150.2, 150.1, 135.3, 134.8, 134.4, 129.3, 129.3, 129.2, 129.2, 129.0, 128.9, 127.7, 127.7, 127.6, 111.7, 111.6, 111.2, 86.9, 85.6, 85.5, 85.0, 84.3, 84.3, 82.9, 82.8, 82.7, 82.6, 78.8, 78.7, 78.4, 73.7, 73.6, 65.1, 65.0, 63.3, 63.2, 62.9, 62.8, 62.7, 43.1, 41.7, 39.9, 39.0, 37.1, 37.1, 30.5, 29.7, 29.6, 20.8, 18.0, 18.0, 12.6, 12.3, 11.7 (only observed peaks). ³¹P NMR (162 MHz, CDCl₃) δ 30.2, 29.1. HRMS–ESI (*m/z*): [M+H]⁺ calcd for C₄₂H₆₂N₄O₁₃PSi, 889.3815; found, 889.3814.

tert-Alkylphosphonate 3af



The product **3af** was purified by flash chromatography on silica gel (80:20:0–50:45:5, hexane/EtOAc/MeOH) (Figure 2; 14.8 mg, 0.015 mmol, 30% isolated yield). The ratio (crude 1.3:1 \rightarrow isolated 2.2:1) of diasteromers was determined by ³¹P-NMR analysis. White amorphous solid. ¹H **NMR** (400 MHz, CDCl₃) δ 8.39–8.20 (m, 2H), 7.47–7.17 (m, 7H), 6.27–6.16 (m, 2H), 5.13 (m, 1H), 4.84 (m, 0.31H), 4.44 (m, 0.69H), 4.22–3.53 (m, 10H), 2.84–2.74 (m, 2H), 2.54–2.32 (m, 4H), 2.11–2.07 (m, 5H), 1.96–1.88 (m, 6H), 1.43–1.42 (m, 9H), 1.10–1.02 (m, 21H). ¹³C **NMR** (100.6 MHz, CDCl₃) δ 170.4, 170.3, 163.2, 163.2, 163.1, 154.8, 150.0, 149.9, 135.5, 134.8, 129.3, 129.3, 129.2, 129.2, 129.0, 129.0, 128.9, 128.9, 127.8, 127.7, 111.7, 111.5, 111.2, 86.9, 85.3, 84.3, 82.7, 79.9, 77.7, 73.5, 70.5, 63.2, 37.0, 37.0, 29.7, 28.4, 28.3, 20.8, 18.0, 18.0, 18.0, 12.6, 12.3, 12.3, 11.8, 11.7 (only observed peaks). ³¹P **NMR** (162 MHz, CDCl₃) δ 30.6, 29.5. **HRMS–ESI** (*m/z*): [M+NH₄]⁺ calcd for C₄₇H₇₄N₆O₁₄PSi, 1005.4764; found, 1005.4765.

tert-Alkylphosphonate 3ag



The product **3ag** was purified by flash chromatography on silica gel (80:20:0–50:45:5, hexane/EtOAc/MeOH) (Figure 2; 20.0 mg, 0.022 mmol, 44% isolated yield). The ratio (crude 1.2:1 \rightarrow isolated 1.2:1) of diasteromers was determined by ³¹P-NMR analysis. White amorphous solid. ¹H **NMR** (400 MHz, CDCl₃) δ 8.48–8.38 (m, 2H), 7.52–7.07 (m, 12H), 6.27–6.20 (m, 2H), 5.19 (m, 0.55H), 5.06 (m, 0.45H), 4.93 (t, *J* = 6.0 Hz, 0.45H), 4.42 (m, 1H), 4.27 (m, 0.55H), 4.17–4.11 (m,

2.55H), 3.87 (m, 1H), 3.63 (m, 0.55H), 3.50 (s, 0.45H), 3.29 (m, 0.45H), 2.50 (m, 0.45H), 2.30 (m, 1H), 2.10–2.02 (m, 6H), 1.97–1.69 (m, 8.55H), 1.12–1.03 (m, 21H). ¹³**C NMR** (100.6 MHz, CDCl₃) δ 170.6, 170.3, 163.5, 163.5, 163.4, 163.3, 150.2, 150.2, 142.7, 142.7, 142.5, 142.5, 140.8, 140.8, 140.3, 140.3, 134.9, 134.8, 134.5, 129.2, 129.1, 129.0, 129.0, 128.5, 128.4, 128.3, 128.2, 127.5, 127.2, 111.7, 111.6, 111.2, 111.2, 87.1, 85.3, 85.3, 84.6, 84.5, 84.3, 83.0, 82.9, 82.7, 82.6, 79.2, 79.2, 79.1, 74.0, 74.0, 65.8, 65.7, 65.1, 65.0, 63.3, 63.2, 51.0, 50.9, 49.6, 49.6, 40.0, 38.8, 38.7, 37.0, 29.7, 25.1, 25.0, 20.8, 18.0, 18.0, 18.0, 12.5, 12.3, 12.2, 12.1, 11.8, 11.7 (only observed peaks). ³¹**P NMR** (162 MHz, CDCl₃) δ 31.1, 30.0. **HRMS–ESI** (*m*/*z*): [M+NH₄]⁺ calcd for C₄₅H₆₅N₅O₁₂PSi, 926.4131; found, 926.4140.

tert-Alkylphosphonate 3ah



The product **3ah** was purified by flash chromatography on silica gel (80:20:0–50:45:5, hexane/EtOAc/MeOH) (Figure 2; 34.1 mg, 0.039 mmol, 77% isolated yield). The ratio (crude 1:1 \rightarrow isolated 1:1) of diasteromers was determined by ³¹P-NMR analysis. Off-white amorphous solid. ¹H **NMR** (400 MHz, CDCl₃) δ 8.46–8.32 (m, 2H), 7.62 (s, 0.5H), 7.45–7.36 (m, 1.5H), 6.38–6.27 (m, 2H), 5.27–5.17 (m, 2H), 4.89 (d, *J* = 4.4 Hz, 0.5H), 4.76 (d, *J* = 4.0 Hz, 0.5H), 4.41–4.19 (m, 4H), 4.03–3.94 (m, 2H), 2.58 (m, 1H), 2.44 (m, 1H), 2.30–2.10 (m, 5H), 1.95–1.91 (m, 6H), 1.63–1.55 (m, 6H), 1.42–1.41 (m, 9H), 1.17–1.08 (m, 21H). ¹³C **NMR** (100.6 MHz, CDCl₃) δ 170.5, 170.3, 163.8, 163.7, 163.6, 154.2, 154.2, 154.1, 150.5, 150.4, 150.4, 150.4, 135.4, 134.9, 134.9, 111.8, 111.7, 111.2, 86.7, 85.8, 85.7, 85.0, 84.7, 84.4, 82.9, 82.8, 82.7, 82.7, 79.9, 79.8, 78.6, 78.5, 78.3, 78.3, 73.9, 73.8, 66.2, 66.1, 65.3, 65.3, 63.4, 63.3, 52.8, 52.8, 51.3, 51.2, 39.8, 39.3, 39.2, 37.0, 36.8, 28.3, 23.8, 23.5, 23.3, 20.8, 18.0, 12.4, 12.3, 12.2, 11.8 (only observed peaks). ³¹P **NMR** (162 MHz, CDCl₃) δ 30.0, 29.2. **HRMS–ESI** (*m*/z): [M+NH₄]⁺ calcd for C₃₉H₆₈N₆O₁₄PSi, 903.4295; found, 903.4296.

tert-Alkylphosphonate 3ai



The product **3ai** was purified by flash chromatography on silica gel (80:20:0–50:45:5, hexane/EtOAc/MeOH) (Figure 2; 41.8 mg, 0.047 mmol, 93% isolated yield). The ratio (crude 1.2:1 \rightarrow isolated 1.1:1) of diastereomers was determined by ³¹P-NMR analysis. Off-white amorphous solid. ¹H NMR (400 MHz, CDCl₃) δ 8.47–8.37 (m, 2H), 7.62 (s, 0.48H), 7.46–7.35 (m, 1.52H), 6.38–6.25 (m, 2H), 5.26–5.21 (m, 2H), 5.10 (s, 0.52H), 4.92 (s, 0.48H), 4.39–4.18 (m, 4H), 4.05–3.93 (m, 2H), 2.63–2.10 (m, 13H), 1.96–1.91 (m, 6H), 1.42 (s, 9H), 1.19–1.08 (m, 21H). ¹³**C NMR** (100.6 MHz, CDCl₃) δ 170.4, 170.3, 163.7, 163.7, 163.6, 153.9, 153.8, 150.5, 150.4, 150.3, 135.4, 135.2, 134.9, 111.7, 111.6, 111.2, 111.2, 86.6, 85.9, 85.9, 85.2, 84.8, 84.4, 84.4, 82.9, 82.9, 82.8, 82.8, 80.0, 80.0, 78.5, 78.4, 78.3, 73.9, 66.0, 65.9, 65.4, 65.3, 63.5, 63.4, 54.2, 54.1, 52.7, 52.5, 39.8, 39.4, 39.4, 37.0, 36.7, 29.9, 29.7, 29.4, 28.3, 28.3, 20.9, 18.0, 16.4, 12.5, 12.3, 11.8 (only observed peaks). ³¹**P NMR** (162 MHz, CDCl₃) δ 27.5, 26.7. **HRMS–ESI** (*m*/*z*): [M+NH4]⁺ calcd for C₄₀H₆₈N₆O₁₄PSi, 915.4295; found, 915.4298.

tert-Alkylphosphonate 3aj



The product **3aj** was purified by flash chromatography on silica gel (80:20:0–50:45:5, hexane/EtOAc/MeOH) (Figure 2; 23.7 mg, 0.028 mmol, 55% isolated yield). The ratio (crude 1.2:1 \rightarrow isolated 1.2:1) of diastereomers was determined by ³¹P-NMR analysis. White amorphous solid. ¹H **NMR** (400 MHz, CDCl₃) δ 8.58–8.33 (m, 2H), 7.58 (m, 0.45H), 7.44 (m, 1H), 7.38 (m, 0.55H), 7.31–7.27 (m, 2H), 7.17–7.05 (m, 3H), 6.41–6.29 (m, 2H), 5.36–5.29 (m, 2H), 4.52–4.31 (m, 3H), 4.22 (s, 1H), 4.05–3.81 (m, 2H), 2.59 (m, 1H), 2.44 (m, 1H), 2.25–2.10 (m, 5H), 1.94–1.90 (m, 6H), 1.58–1.44 (m, 6H), 1.14–1.01 (m, 21H). ¹³C **NMR** (100.6 MHz, CDCl₃) δ 170.5, 170.4, 163.4, 163.3, 153.1, 153.0, 153.0, 152.9, 150.2, 135.2, 134.8, 134.8, 129.2, 124.9, 124.2, 111.8, 111.7, 111.3, 111.2, 86.7, 86.0, 86.0, 84.8, 84.7, 84.5, 84.3, 83.0, 82.9, 82.8, 82.7, 79.7, 79.6, 78.8, 78.8, 78.7, 78.0, 77.8, 74.0, 73.9, 66.2, 66.1, 65.7, 65.6, 63.5, 63.4, 40.0, 39.5, 39.4, 37.2, 37.0, 29.7, 29.6, 23.8, 23.8, 23.3, 23.3, 22.6, 22.6, 22.2, 22.2, 20.9, 20.8, 18.0, 17.9, 12.4, 12.3, 11.8, 11.7 (only observed peaks). ³¹P **NMR** (162 MHz, CDCl₃) δ 25.9, 25.3. **HRMS–ESI** (*m*/*z*): [M+H]⁺ calcd for C₄₀H₆₀N₄O₁₃PSi, 863.3658; found, 863.3659.

7. X-ray Structure of (R_P)-3aa

Details of the crystal data and a summary of the intensity data collection parameters for (R_P) -3aa are listed in Table S1. A suitable crystal obtained by recrystallization from acetonitrile and water was mounted with mineral oil on a MiTeGen MicroMounts and transferred to the goniometer of the kappa goniometer of a RIGAKU XtaLAB Synergy-S system with 1.2 kW MicroMax-007HF microfocus rotating anode (Graphite-monochromated Mo K α radiation ($\lambda = 0.71073$ Å)) and HyPix-6000HE hybrid photon-counting detector. Cell parameters were determined and refined, and raw frame data were integrated using CrysAlis^{Pro} (Agilent Technologies, 2010) and a multi-scan absorption correction using SCALE3 ABSPACK was applied. The structures were solved by direct methods with SHELXT¹¹ and refined by full-matrix least-squares techniques against F^2 (SHELXL-2018/3)¹² by using Olex2 software package.¹³ The intensities were corrected for Lorentz and polarization effects. All non-hydrogen atoms were refined with anisotropic displacement parameters. The hydrogen atoms were refined isotropically on calculated positions using a riding model with their U_{iso} values constrained to 1.5 times the U_{eq} of their pivot atoms for terminal sp³ carbon atoms and 1.2 times for all other carbon atoms. Crystallographic data for the structures reported in this paper have been deposited with the Cambridge Crystallographic Data Centre. CCDC 2263561 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data request/cif.



	(<i>R</i> _P)- 3 aa
CCDC No.	2263561
formula	$C_{40}H_{59}N_4O_{12}PSi$
fw	846.97
$T(\mathbf{K})$	123(2)
λ (Å)	0.71073
cryst syst	orthorhombic
space group	$P2_{1}2_{1}2_{1}$
<i>a</i> (Å)	9.8268(2)
<i>b</i> (Å)	13.5743(4)
<i>c</i> (Å)	32.2626(14)
α (deg)	90
β (deg)	90
$\gamma(\text{deg})$	90
$V(Å^3)$	4303.6(2)
Ζ	4
$D_{\text{calc}} \left(\mathbf{g} \cdot \mathbf{cm}^{-3} \right)$	1.307
$\mu (\mathrm{mm}^{-1})$	0.157
F(000)	1808
cryst size (mm ³)	0.2 imes 0.04 imes 0.01
2θ range (deg)	5.12 to 54.97
reflns collected	22102
indep reflns/R _{int}	9462 / 0.0632
params	534
GOF on F^2	1.050
$R_1, wR_2 [I > 2\sigma(I)]$	0.0692, 0.1709
R_1 , wR_2 (all data)	0.0909, 0.1798
Flack parameter	-0.11(8)

Table S1. Crystallographic data and structure refinement details of (R_P) -3aa

8. Derivatization of tert-Alkylphosphonates to the Phosphoramidites

Procedure for synthesis of (S_P)-3aa-3 and (R_P)-3aa-3



Supplementary Fig. 3. Derivatization of tert-alkylphosphonates to the phosphoramidites

Deprotection. (S_P)-**3aa** (250 mg, 0.30 mmol) was disolved in ammonia solution (28% NH₃ aq.: 40% MeNH₂ aq. = 1:1). Stirred for 30 min, the reaction mixture was evaporated to remove solvents and reactants. The residue was used for the desilylation without further purification. The residue was disollved in THF (0.7 mL) and the THF solution of tetrabutylammonium fluoride (0.44 ml, 0.44 mmol) was added to the solution. The reaction mixture was stirred for 90 min and then was evaporated. The crude mixture was purified by silica-gel column chromatography (silica gel, hexane/EtOAc = 50:50 to EtOAc only, then EtOAc/MeOH = 100:0 to 90:10) to obtain (S_P)-**3aa-1** (120 mg, 0.19 mmol, 63%). (R_P)-**3aa-1** was synthesized using the same protocol (46 mg, 0.07 mmol, 60% from 0.12 mmol scale synthesis).

DMTr protection. To a solution of (S_P) -**3aa-1** (120 mg, 0.19 mmol) in dry pyridine (2.0 mL) was added 4,4'-{chloro(phenyl)methylene}bis(methoxybenzene) (190 mg, 0.56 mmol) at room temperature. After stirring for 16 hours under a dry atmosphere, the reaction was quenched with MeOH (1 mL) and then the solvent was evaporated. The crude product was purified by column chromatography (silica gel, hexane/EtOAc = 20:80 to EtOAc only, then EtOAc/MeOH = 100:0 to 90:10) to give (S_P)-**3aa-2** (170 mg, 0.18 mmol, 97 %) as amorphous solid. (R_P)-**3aa-2** was synthesized using the same protocol (42 mg, 0.044 mmol, 82% from 0.05 mmol scale synthesis).

Phosphoramidation. To a solution of (S_P) -**3aa-2** (160 mg, 0.17 mmol) in dry MeCN (4.0 ml) was added DIPEA (0.10 ml, 0.59 mmol) and 3-[{chloro(diisopropylamino)phosphaneyl}oxypropanenitrile] (0.094 ml, 0.34 mmol) at 0 °C. Cooling bath was removed and the mixture was allowed to be stirred at room temperature under dry nitrogen for 1 h. The reaction mixture was washed with hexane (5mL). The resulting oil was purified by column chromatography (silica gel, pre-wetted with hexane/EtOAc/triethylamine = 25:74:1, eluted with hexane/EtOAc = 25:75 to EtOAc only) to give (S_P)-**3aa-3** (110 mg, 0.098 mmol, 58%) as a colorless amorphous solid. (R_P)-**3aa-3** was synthesized using the same protocol, but the further purification with column chromatography (silica gel, pre-wetted with hexane/EtOAc/triethylamine = 25:74:1, eluted with hexane/EtOAc = 25:75 to EtOAc only) was required to result in lower yield. (12 mg, 0.04 mmol, 26% from 0.04 mmol scale synthesis).

9. Characterization Data for Phosphoramidites

(S_P)-3aa-1



Colorless amorphous solid. The sample contains inseprable impurities. ¹H NMR (400 MHz, CD₃OD) δ 7.76 (m, 1H), 7.58–7.56 (m, 2H), 7.37–7.34 (m, 3H), 7.25 (m, 1H), 6.23–6.17 (m, 2H), 4.86 (m, 1H), 4.28 (m, 1H), 4.18–4.05 (m, 3H), 3.99 (m, 1H), 3.69–3.68 (m, 2H), 2.22 (m, 1H), 2.11–2.04 (m, 3H), 1.89–1.85 (m, 6H), 1.70–1.65 (m, 6H). ¹³C NMR (100.6 MHz, CD₃OD) δ 166.3, 166.3, 152.3, 152.2, 141.5 (d, $J_{C-P} = 5.1$ Hz), 137.8, 137.5, 129.5 (×2C) (d, $J_{C-P} = 2.8$ Hz), 128.9 (×2C) (d, $J_{C-P} = 5.4$ Hz), 128.4 (d, $J_{C-P} = 2.8$ Hz), 111.9, 111.8, 87.4 (d, $J_{C-P} = 3.5$ Hz), 86.5, 86.2 (d, $J_{C-P} = 6.5$ Hz), 85.9, 79.1 (d, $J_{C-P} = 7.6$ Hz), 71.8, 67.3 (d, $J_{C-P} = 7.8$ Hz), 62.4, 40.4 (d, $J_{C-P} = 135.8$ Hz), 40.4, 39.3 (d, $J_{C-P} = 4.6$ Hz), 24.4 (d, $J_{C-P} = 3.8$ Hz), 24.1 (d, $J_{C-P} = 4.1$ Hz), 12.7, 12.4. ³¹P NMR (162 MHz, CD₃OD) δ 33.7. HRMS–ESI (*m*/*z*): [M+H]⁺ calcd for C₂₉H₃₈N₄O₁₁P, 649.2269; found, 649.2288.

(S_P)-3aa-2



Colorless amorphous solid. ¹H NMR (400 MHz, CDCl₃) δ 9.09–8.98 (m, 2H), 7.58–7.56 (m, 2H), 7.39–7.19 (m, 13H), 7.08 (s, 1H), 6.84–6.82 (m, 4H), 6.30 (m, 1H), 6.13 (m, 1H), 4.81 (m, 1H), 4.19 (m, 1H), 4.12 (m, 1H), 3.99 (m, 1H), 3.85–3.78 (m, 8H), 3.42–3.34 (m, 3H), 2.28 (s, 1H), 2.10–2.08 (m, 2H), 1.95–1.89 (m, 4H), 1.69–1.65 (m, 6H), 1.38 (s, 3H). ¹³C NMR (100.6 MHz, CDCl₃) δ 163.6, 158.7, 158.7, 150.4, 150.1, 144.1, 139.9, 139.9, 135.3, 135.2, 135.1, 135.0, 130.1, 128.5, 128.5, 128.1, 128.0, 127.7, 127.7, 127.6, 127.5, 127.2, 113.3, 111.6, 111.1, 87.1, 85.0, 85.0, 84.8, 84.6, 84.2, 77.8, 77.7, 77.2, 70.5, 64.8, 63.1, 55.3, 40.0, 39.6, 38.7, 38.7, 38.7, 24.0, 24.0, 23.7, 23.7, 12.6, 11.6 (only

observed peaks). ³¹P NMR (162 MHz, CDCl₃) δ 34.7. HRMS–ESI (*m/z*): [M+NH₄]⁺ calcd for C₅₀H₅₉N₅O₁₃P, 968.3842; found, 968.3840.

 (S_P) -3aa-3



Colorless amorphous solid. ¹H NMR (400 MHz, CDCl₃) δ 8.45 (brs, 2H), 7.58–7.56 (m, 2H), 7.39–7.11 (m, 14H), 6.83–6.81 (m, 4H), 6.29 (m, 1H), 6.19 (m, 1H), 4.82 (m, 1H), 4.36 (m, 1H), 4.11–4.03 (m, 3H), 3.93–3.57 (m, 11H), 3.35–3.30 (m, 2H), 2.65–2.60 (m, 2H), 2.38 (m, 1H), 2.07–2.00 (m, 2H), 1.92–1.80 (m, 4H), 1.70–1.65 (m, 6H), 1.34–1.17 (m, 15H). ¹³C NMR (100.6 MHz, CDCl₃) δ 163.4, 163.3, 158.7, 158.7, 150.1, 150.0, 149.9, 144.1, 144.0, 140.2, 140.1, 140.1, 140.1, 135.2, 135.2, 135.1, 135.1, 134.9, 134.9, 130.1, 128.5, 128.1, 128.0, 127.7, 127.6, 127.5, 127.4, 127.2, 117.6, 113.3, 111.5, 111.3, 111.2, 87.1, 85.2, 85.0, 84.9, 84.3, 84.0, 83.9, 77.9, 77.9, 77.2, 73.2, 73.0, 72.9, 72.7, 64.6, 64.5, 64.5, 63.1, 63.1, 58.2, 58.1, 58.0, 57.9, 55.3, 43.4, 43.3, 40.0, 39.3, 39.2, 38.8, 38.7, 30.9, 24.6, 24.5, 24.2, 24.2, 23.7, 23.6, 23.5, 23.5, 20.5, 20.4, 20.3, 20.3, 12.6, 12.5, 11.5 (only observed peaks). ³¹P NMR (162 MHz, CDCl₃) δ 149.3, 149.1, 34.4, 34.4. HRMS–ESI (*m*/*z*): [M+NH₄]⁺ calcd for C₅₉H₇₆N₇O₁₄P₂, 1168.4920; found, 1168.4934.

(R_P)-3aa-1



Colorless amorphous solid. The sample contains inseprable impurities. ¹H NMR (400 MHz, CD₃OD) δ 7.74 (m, 1H), 7.58–7.56 (m, 2H), 7.49 (m, 1H), 7.37–7.35 (m, 2H), 7.28 (m, 1H), 6.24–6.19 (m, 2H), 4.85 (m, 1H), 4.26 (m, 1H), 4.13 (m, 1H), 4.04 (m, 1H), 3.96 (m, 1H), 3.82 (m, 1H), 3.58 (m, 1H), 3.43 (m, 1H), 2.38 (m, 1H), 2.23–2.10 (m, 3H), 1.88–1.84 (m, 6H), 1.69–1.65 (m, 6H). ¹³C NMR (100.6 MHz, CDCl₃) δ 166.3, 166.3, 152.3, 152.2, 141.6 (d, $J_{C-P} = 5.1$ Hz), 137.7 (×2C), 129.4 (×2C) (d, $J_{C-P} = 2.7$ Hz), 128.9 (×2C) (d, $J_{C-P} = 5.4$ Hz), 128.4 (d, $J_{C-P} = 3.0$ Hz), 111.9, 111.9, 87.1 (d, $J_{C-P} = 6.0$ Hz), 86.5, 86.2 (d, $J_{C-P} = 5.2$ Hz), 86.0, 79.4 (d, $J_{C-P} = 7.6$ Hz), 71.6, 68.0 (d, $J_{C-P} = 7.8$ Hz), 62.5, 40.5 (d, $J_{C-P} = 136.0$ Hz), 40.5, 40.2 (d, $J_{C-P} = 2.1$ Hz), 24.4 (d, $J_{C-P} = 3.7$ Hz), 24.1

(d, $J_{C-P} = 3.9 \text{ Hz}$), 12.5, 12.5. ³¹**P** NMR (162 MHz, CD₃OD) δ 33.3. HRMS–ESI (*m*/*z*): [M+H]⁺ calcd for C₂₉H₃₈N₄O₁₁P, 649.2269; found, 649.2286.

 $(R_{\rm P})$ -3aa-2



Pale yellow amorphous solid. ¹H NMR (400 MHz, CDCl₃) δ 9.62 (brs, 1H), 9.21 (brs, 1H), 7.52– 7.45 (m, 3H), 7.30–7.16 (m, 12H), 7.06 (m, 1H), 6.85–6.83 (m, 4H), 6.34 (m, 1H), 6.21 (m, 1H), 4.66 (m, 1H), 4.44 (m, 1H), 4.25 (m, 1H), 4.12–3.99 (m, 3H), 3.81–3.79 (m, 7H), 3.26 (m, 1H), 2.78 (m, 1H), 2.54 (m, 1H), 2.44–2.29 (m, 2H), 2.08 (m, 1H), 1.93 (s, 3H), 1.64–1.57 (m, 6H), 1.29 (s, 3H). ¹³C NMR (100.6 MHz, CDCl₃) δ 163.7, 163.5, 163.5, 158.8, 158.8, 151.1, 150.3, 143.8, 140.0, 139.9, 135.6, 135.1, 135.0, 134.9, 130.1, 128.3, 128.3, 128.2, 128.0, 127.5, 127.4, 127.4, 127.3, 127.3, 113.3, 112.2, 111.1, 87.3, 85.3, 84.8, 84.7, 84.4, 84.3, 84.3, 79.7, 79.7, 77.2, 70.8, 65.4, 65.3, 63.3, 55.3, 40.3, 40.2, 39.0, 24.4, 24.4, 23.4, 23.4, 12.5, 11.5 (only observed peaks). ³¹P NMR (162 MHz, CDCl₃) δ 34.0. HRMS–ESI (*m*/*z*): [M+NH₄]⁺ calcd for C₅₀H₅₉N₅O₁₃P, 968.3842; found, 968.3841.

(*R*_P)-3aa-3



(*R*_P)-**3aa-3**

Colorless amorphous solid. ¹H NMR (400 MHz, CDCl₃) δ 8.44–8.40 (m, 2H), 7.48–7.10 (m, 16H), 6.85–6.82 (m, 4H), 6.36 (m, 1H), 6.19 (m, 1H), 4.90 (m, 1H), 4.45 (m, 1H), 4.21–4.06 (m, 3H), 3.86–3.59 (m, 11H), 3.26 (m, 1H), 2.87 (m, 1H), 2.65–2.62 (m, 2H), 2.51–2.34 (m, 3H), 2.01–1.88 (m, 4H), 1.62–1.56 (m, 6H), 1.30–1.18 (m, 15H). ¹³C NMR (100.6 MHz, CDCl₃) δ 163.5, 163.3, 158.8, 150.2, 150.2, 150.0, 143.9, 140.3, 140.2, 136.0, 135.8, 135.3, 135.1, 134.9, 130.1, 128.3, 128.3, 128.2, 128.0, 127.6, 127.5, 127.5, 127.5, 127.3, 117.8, 113.1, 111.6, 111.2, 111.1, 87.2, 85.7, 84.5, 84.4, 84.2, 78.7, 78.6, 78.4, 77.2, 73.2, 65.5, 63.3, 58.1, 57.9, 55.3, 43.4, 43.4, 43.3, 43.2, 40.2, 40.2, 39.8, 39.4, 39.4, 39.1, 38.8, 38.8, 24.6, 24.5, 24.5, 24.4, 23.6, 20.5, 20.4, 20.4, 20.4, 12., 3 11.5, 11.4 (only observed peaks). ³¹P NMR (162 MHz, CDCl₃) δ 149.3, 148.9, 33.4, 33.3. HRMS–ESI (*m*/*z*): [M+NH₄]⁺ calcd for C₅₉H₇₆N₇O₁₄P₂, 1168.4920; found, 1168.4943.

10. Procedure for Automated Solid-Support Synthesis of Oligonucleotides

The automated solid-support synthesis of oligonucleotides were performed on nS8-II (GeneDesign). The detailed protocol for nS8-II was given in the table below. All the oligonucleotides were synthesized using low-loaded UnylinkerTM universal solid support (0.5 umol, 42.6 umol/g, ChemGenes, N-4000-10). After the synthetic cycle, the solid support was dried with an argon gas flush and placed into a 2 mL microtube. 500 uL of ammonia methyl amine (AMA) solution (28% NH₃ aq./ 40% MeNH₂ aq. = 1/1) was added to the tube and the support was treated for 30 minutes at 58 °C. The remaining ammonia and MeNH₂ was evaporated and purified with the cartridge purification system (Glen-PakTM DNA Purification Cartridge, #60-5200, according to the manual provided) to afford aqueous solution containing the purified oligonucleotide. UV absorbance of the solution was measured and then the sample was lyophilyzed to afford a white powder. Yield was calculated based on absorbance of 260 nm, in which the molar absorption coefficient of the oligonucleotides (**Oligo-1-8**) was calculated from the known 260 nm absorption coefficient of thymine in aqueous media.

Synthesis cycle for oligonucleotides (0.5 umol scale)

Step	Reaction	Reagent	Volume (1CV = 500 uL)	Reaction time
1	Detritylation	Dichloroacetic Acid-Toluene (3:97)	2 CV (incubation twice)	90 sec (60 + 30 seq)
2	Coupling	Activator solution: 0.1M Amidite solution = 40:60	12 eq.	4 min for (R_P/S_P) -3aa-3 1 min for dT amidite
3	Oxidation	Iodine Solution (abt. 0.05mol/L)][Pyridi ne:Water(9:1)	1 CV (incubation)	30 sec
4	Capping	1-Methylimidazole-Acetonitrile (2:8) + Acetic Anhydride-2,6-Lutidine- Acetonitrile (2:3:5)	1 CV (incubation)	90 sec

Note: Before starting the coupling cycle, conduct deblocking of DMTr group on solid-support sufficiently in order to prevent generation of -1nt oligomer byproduct. The dimer amidite (R_P/S_P)-3aa-3 was dehydrated by azeotropic distillation and dried in vacuo with P_2O_5 before use.

UPLC-MS's LC charts and ESI-QTOF MS spectra of oligonucleotides

Analysis condition	ons with Waters UPLC MS systems
System	Waters, UPLC Xevo G2-XS QTof
column	ACQUITY UPLC OST C18 Column, 1.7 $\mu m,$ 2.1 x 50 mm
Buffer	A····240 mM HFIP, 7 mM TEA (5% MeOH)
	B····240 mM HFIP, 7 mM TEA (100% MeOH)
Gradient	10 to 80 for 6min
Flow rate	0.2 ml/min
Column oven ter	nperature 60 °C
Detector	UV 260 nm

Oligo-1 (R_P)-TTTTTTTTTTTT_{Alk}T







Oligo-2 (S_P)-TTTTTTTTTTT_{Alk}T



S33





Oligo-3 (R_P)-TTTTTT_{Alk}TTTTT




Oligo-4 (S_P)-TTTTT_{Alk}TTTTT







Oligo-5 (S_P,S_P)-T_{Alk}TTTTTTTTT_{Alk}T







Oligo-6 TTTTTTTTTT







Oligo-7 TTTTTTTTTTT







Oligo-8 TTTTTTTTTTT_{MOP}T







Synthesized oligonucleotides	MW: M-H (calcd)	MW: M-H (obsd)	crude yield (%)	retention time on LC (min)
Oligo-1 (<i>R</i> _P)-TTTTTTTTTT _{Alk} T	3079.58	3079.14	35	3.09
Oligo-2 (S _P)-TTTTTTTTTTT _{Alk} T	3079.58	3079.12	43	3.14
Oligo-3 (<i>R</i> _P)-TTTTT _{Alk} TTTTT	3079.58	3079.12	47	2.80
Oligo-4 (S _P)-TTTTT _{Alk} TTTTT	3079.58	3079.12	31	2.83
Oligo-5 (S _P ,S _P)-T _{Alk} TTTTTTTT _{Alk} T	3181.66	3181.18	32	3.66
Oligo-6 TTTTTTTTT	2977.50	2977.14	52	2.04
Oligo-7 TTTTTTTTT _{OEt} T	3005.53	3005.10	25	2.63*
Oligo-8 TTTTTTTTTT _{MOP} T	3033.56	3033.14	37	2.68*

* LC diagram showed shouldered peaks in these compounds. MS spectra of each compound was the same, suggesting that they are diastereomers with a different stereo configuration around backbone phosphorous atom.

Supplementary Fig. 4. Summary of Yields and Retention Time of Oligo-1-8

Comparizon between other charge-neutral backbonemodified Oligos (Oligo1,2 vs. Oligo-7,8)

Retention time (lipophilicity) of **Oligo-1** and **Oligo-2** was increased compared to the ethyltriester- and MOP-modified oligos (**Oligo-7** and **8**), and the retention time gap due to the difference between the S_P and R_P configurations was also expanded. The influence of chirality on global hydrophilicity/hydrophobicity seemed to be increased due to its large size, which may also contribute to protein binding profiles and lead to eutomer/distomer differences as a pharmaceutical.



11. Detection of Alkylsulfonium



Supplementary Fig. 5. Detection of Alkylsulfonium

In a glovebox, to an oven-dried vial equipped with a stirring bar was added **PTH2** (13.2 mg, 0.05 mmol), redox-active ester **2a** (46.4 mg, 0.15 mmol) and LiBF₄ (4.7 mg, 0.15 mmol). Then, MeCN (300 μ L) and DCM (200 μ L) were added to the reaction mixture. After sealing the vial with a cap and removed from the glove box, the reaction was stirred and irradiated with a 34W blue LED with a cooling UC reactor to keep the temperature at 10 °C (Supplementary Fig. 2). After 4 h, the reaction solution was directly used for MS analysis (HRMS–ESI). **PTH2-2a**: **HRMS–ESI** (m/z): [M–BF₄]⁺ calcd for C₂₆H₂₄NS, 382.1624; found, 382.1614.

12. Effects of Additives on Conversion of Redox-Active Esters

In a glovebox, to an oven-dried vial with a stirring bar was added **PTH2** (13.2 mg, 0.05 mmol), phosphite **1a** (42.9 mg, 0.05 mmol), redox-active ester **2a** (46.4 mg, 0.15 mmol), LiBF₄ (4.7 mg, 0.15 mmol) and thymine (6.3 mg, 0.05 mmol). Then, MeCN (300 μ L) and DCM (200 μ L) were added to the reaction mixture. After sealing the vial with parafilm, the reaction mixture was stirred and irradiated with a 34W blue LED with a cooling UC reactor to keep the temperature at 10 °C (Supplementary Fig. 2). After 4 h, the solvents were removed under reduced pressure and the residue was analyzed by ¹H NMR. The increase in conversion of **2a** to 28% was observed with the addition of thymine compared to without thymine (11%).

13. Comparison with Other Carbocation Methods

Comparison with Aggarwal's Method. Tertiary alkylation of phosphite **1a-1** was conducted with reference to the reported procedure.¹⁴ In a glovebox, to an oven-dried vial with a stirring bar was added photoredox catalyst 4CzIPN (0.79 mg, 0.001 mmol), phosphite **1a-1** (42.9 mg, 0.05 mmol) and redox-active ester **2a** (46.4 mg, 0.15 mmol). Then, MeCN (500 μ L) and TFA (5.7 μ L, 0.075 mmol) were added to the reaction mixture. After sealing the vial with parafilm, the reaction mixture was stirred and irradiated with a 34W blue LED (3 cm away) with a cooling fan to keep the temperature around 40 °C. After 2 h, the solvents were removed under reduced pressure and the residue was analyzed by 1H NMR. However, the desired product **3aa** was not obtained, and the decomposition products of **1a-1** were observed.

Comparison with methods using Lewis acid. Tertiary alkylation of phosphite **1a-1** was conducted with reference to the reported procedure.^{15,16} In a glovebox, to an oven-dried vial with a stirring bar was added phosphite **1a-1** (42.9 mg, 0.05 mmol) and 2-phenyl-2-propanol (**5a**) (20.4 mg, 0.15 mmol). Then, toluene (500 μ L) and Lewis acid TMSOTf (1.81 μ L, 0.01 mmol) or ZnI₂ (23.9 mg, 0.075

mmol) were added to the reaction mixture. After sealing the vial with parafilm, the reaction mixture was stirred at 110 °C. After 15–24 h, the solvents was removed under reduced pressure and the residue was analyzed by 1H NMR. However, the desired product **3aa** was not obtained, giving a complex mixture.



14. The Effects of Chiral Leaving Groups

Supplementary Fig. 6. The Effects of Chiral Leaving Groups

Chiral alcohols were prepared from chiral styrene oxide.¹⁷ Phosphite (*R*)/(*S*)-**1a-1** having chiral leaving groups were syshesized by the above mentioned procedure (Supplementary Fig. 1). In a glovebox, to an oven-dried vial with a stirring bar was added **PTH2** (13.2 mg, 0.05 mmol), phosphite (*R*)-**1a-1** or (*S*)-**1a-1** (42.9 mg, 0.05 mmol), redox-active ester **2a** (46.4 mg, 0.15 mmol) and LiBF4 (4.7 mg, 0.05 mmol). Then, MeCN (300 μ L) and DCM (200 μ L) were added to the reaction mixture. After sealing the vial with parafilm, the reaction mixture was stirred and irradiated with a 34W blue LED with a cooling UC reactor to keep the temperature at 10 °C (Supplementary Fig. 2). After 18 h, the solvents were removed under reduced pressure and the yield was determined by ¹H-NMR analysis. The effect of the chiral leaving group on this reaction was investigated, but no significant difference in the yield and the ratio of diastereomers of the alkylated product **3aa** was observed.

15. Examination of Catalytic Reactions

When simple phosphite **1g** was used as a nucleophile, oxidative alkylation proceeded catalytically with high efficiency (Supplementary Fig. 7A). On the other hand, when H-phosphonate **1h** was used as a nucleophile instead of phosphite, no alkylated product was obtained (Supplementary Fig. 7B). **Procedure.** In a glovebox, to an oven-dried vial with a stirring bar was added **PTH1** (3.3 mg, 0.01 mmol), trihexyl phosphite **1g** (74.3 μ L, 0.2 mmol) or dibutyl phosphite **1h** (39.2 μ L, 0.2 mmol), redox-active ester **2a** (92.8 mg, 0.3 mmol), LiBF₄ (0.9 mg, 0.01 mmol) and DCM (600 μ L). After sealing the vial with parafilm, the reaction mixture was stirred and irradiated with a 34W blue LED with a cooling fan to keep the temperature around 40 °C. After 16 h, the solvents were removed under reduced pressure and the residue was analyzed by ¹H NMR.



Supplementary Fig. 7. Examination of Catalytic Reactions

16. Examination of the Addition of Trapping Reagent for Carbocation

PTH-catalytic reactions were investigated by adding a stoichiometric amount of sulfilimine, used in the stabilized cation pool method,¹⁸ as a trapping reagent for the carbocation, but the yield was not improved (Supplementary Fig. 8).

Procedure. In a glovebox, to an oven-dried vial with a stirring bar was added **PTH1** (1.63 mg, 0.005 mmol), phosphite **1a-1** (42.9 mg, 0.05 mmol), redox-active ester **2a** (46.4 mg, 0.15 mmol) or **2k** (37.1 mg, 0.15 mmol), LiBF₄ (0.47 mg, 0.005 mmol) and sulfilimine (17.8 mg, 0.05 mmol). Then, MeCN (300 μ L) and DCM (200 μ L) were added to the reaction mixture. After sealing the vial with parafilm, the reaction mixture was stirred and irradiated with a 34W blue LED with a cooling UC reactor to keep the temperature at 10 °C (Supplementary Fig. 2). After 18 h, the solvents were removed under reduced pressure and the residue was analyzed by ¹H NMR.



Supplementary Fig. 8. Examination of the Addition of Trapping Reagent for Carbocation

17. Unsuccessful Substrates



Supplementary Fig. 9. Unsuccessful Substrates



¹H NMR (400 MHz, CDCl₃) spectrum of **2b**



¹³C NMR (100.6 MHz, CDCl₃) spectrum of **2b**



¹H NMR (400 MHz, CDCl₃) spectrum of **2c**



¹³C NMR (100.6 MHz, CDCl₃) spectrum of **2c**



¹H NMR (400 MHz, CDCl₃) spectrum of **2d**



¹³C NMR (100.6 MHz, CDCl₃) spectrum of **2d**



¹H NMR (400 MHz, CDCl₃) spectrum of **2e**



¹³C NMR (100.6 MHz, CDCl₃) spectrum of **2e**



¹H NMR (400 MHz, CDCl₃) spectrum of **2g**



 ^{13}C NMR (100.6 MHz, CDCl₃) spectrum of 2g



¹H NMR (400 MHz, CDCl₃) spectrum of **2j**



¹³C NMR (100.6 MHz, CDCl₃) spectrum of **2j**



¹H NMR (400 MHz, CDCl₃) spectrum of **S3-1**



¹³C NMR (100.6 MHz, CDCl₃) spectrum of S3-1



³¹P NMR (162 MHz, CDCl₃) spectrum of **S3-1**



¹H NMR (400 MHz, CDCl₃) spectrum of **1a-1**



¹³C NMR (100.6 MHz, CDCl₃) spectrum of **1a-1**



³¹P NMR (162 MHz, CDCl₃) spectrum of **1a-1**



¹H NMR (400 MHz, CDCl₃) spectrum of **S2-2**



¹³C NMR (100.6 MHz, CDCl₃) spectrum of **S2-2**



³¹P NMR (162 MHz, CDCl₃) spectrum of **S2-2**


¹H NMR (400 MHz, CDCl₃) spectrum of **S3-2**



¹³C NMR (100.6 MHz, CDCl₃) spectrum of S3-2



³¹P NMR (162 MHz, CDCl₃) spectrum of **S3-2**



¹H NMR (400 MHz, CDCl₃) spectrum of **1a-2**



¹³C NMR (100.6 MHz, CDCl₃) spectrum of 1a-2



³¹P NMR (162 MHz, CDCl₃) spectrum of **1a-2**



¹H NMR (400 MHz, CDCl₃) spectrum of **S2-3**



 ^{13}C NMR (100.6 MHz, CDCl₃) spectrum of **S2-3**



³¹P NMR (162 MHz, CDCl₃) spectrum of **S2-3**



¹H NMR (400 MHz, CDCl₃) spectrum of **S3-3**



¹³C NMR (100.6 MHz, CDCl₃) spectrum of **S3-3**



³¹P NMR (162 MHz, CDCl₃) spectrum of **S3-3**



¹H NMR (400 MHz, CDCl₃) spectrum of **1a-3**



¹³C NMR (100.6 MHz, CDCl₃) spectrum of 1a-3



³¹P NMR (162 MHz, CDCl₃) spectrum of **1a-3**



¹H NMR (400 MHz, CDCl₃) spectrum of **1a-4**



¹³C NMR (100.6 MHz, CDCl₃) spectrum of 1a-4



³¹P NMR (162 MHz, CDCl₃) spectrum of **1a-4**



¹H NMR (400 MHz, CDCl₃) spectrum of *N*-Benzoyl-5'-O-TIPS-5-methyl-2'-deoxycytidine



¹³C NMR (100.6 MHz, CDCl₃) spectrum of *N*-Benzoyl-5'-*O*-TIPS-5-methyl-2'-deoxycytidine



¹H NMR (400 MHz, CDCl₃) spectrum of *N*-Benzoyl-5'-*O*-TIPS-5-methyl-2'-deoxycytidine Phosphoramidite



¹³C NMR (100.6 MHz, CDCl₃) spectrum of *N*-Benzoyl-5'-*O*-TIPS-5-methyl-2'-deoxycytidine Phosphoramidite



³¹P NMR (162 MHz, CDCl₃) spectrum of *N*-Benzoyl-5'-*O*-TIPS-5-methyl-2'-deoxycytidine Phosphoramidite



¹H NMR (400 MHz, CDCl₃) spectrum of **1b**



¹³C NMR (100.6 MHz, CDCl₃) spectrum of **1b**



³¹P NMR (162 MHz, CDCl₃) spectrum of **1b**



¹H NMR (400 MHz, CDCl₃) spectrum of **1c**



 13 C NMR (100.6 MHz, CDCl₃) spectrum of **1c**



³¹P NMR (162 MHz, CDCl₃) spectrum of **1c**



¹H NMR (400 MHz, CDCl₃) spectrum of **1d**



¹³C NMR (100.6 MHz, CDCl₃) spectrum of 1d



³¹P NMR (162 MHz, CDCl₃) spectrum of 1d



¹H NMR (400 MHz, CDCl₃) spectrum of *N*⁶-Benzoyl-5'-*O*-TIPS-2'-deoxyadenosine Phosphoramidite



¹³C NMR (100.6 MHz, CDCl₃) spectrum of *N*⁶-Benzoyl-5'-*O*-TIPS-2'-deoxyadenosine Phosphoramidite



³¹P NMR (162 MHz, CDCl₃) spectrum of *N*⁶-Benzoyl-5'-*O*-TIPS-2'-deoxyadenosine Phosphoramidite



¹H NMR (400 MHz, CDCl₃) spectrum of **1e**


¹³C NMR (100.6 MHz, CDCl₃) spectrum of **1e**



³¹P NMR (162 MHz, CDCl₃) spectrum of **1e**



¹H NMR (400 MHz, CDCl₃) spectrum of *N*²-Isobutyryl-*O*⁶-(diphenylcarbamoyl)-5'-*O*-TIPS-2'-deoxyguanosine



 $^{13}\text{C NMR} (100.6 \text{ MHz}, \text{CDCl}_3) \text{ spectrum of } N^2 \text{-} \textbf{Isobutyryl-} O^6 \text{-} (\textbf{diphenylcarbamoyl}) \text{-} \textbf{5'} \text{-} O \text{-} \textbf{TIPS-2'} \text{-} \textbf{deoxyguanosine}$



¹H NMR (400 MHz, CDCl₃) spectrum of *N*²-Isobutyryl-*O*⁶-(diphenylcarbamoyl)-5'-*O*-TIPS-2'-deoxyguanosine Phosphoramidite



¹³C NMR (100.6 MHz, CDCl₃) spectrum of *N*²-Isobutyryl-*O*⁶-(diphenylcarbamoyl)-5'-*O*-TIPS-2'-deoxyguanosine Phosphoramidite



³¹P NMR (162 MHz, CDCl₃) spectrum of N²-Isobutyryl-O⁶-(diphenylcarbamoyl)-5'-O-TIPS-2'-deoxyguanosine Phosphoramidite



¹H NMR (400 MHz, CDCl₃) spectrum of **1f**



¹³C NMR (100.6 MHz, CDCl₃) spectrum of **1f**



³¹P NMR (162 MHz, CDCl₃) spectrum of **1f**



¹H NMR (400 MHz, CDCl₃) spectrum of **3aa**



¹³C NMR (100.6 MHz, CDCl₃) spectrum of **3aa**



³¹P NMR (162 MHz, CDCl₃) spectrum of **3aa**



¹H NMR (400 MHz, CDCl₃) spectrum of **3ba-d1**



¹³C NMR (100.6 MHz, CDCl₃) spectrum of **3ba-d1**



³¹P NMR (162 MHz, CDCl₃) spectrum of **3ba-d1**



¹H NMR (400 MHz, CDCl₃) spectrum of **3ba-d2**



¹³C NMR (100.6 MHz, CDCl₃) spectrum of **3ba-d2**



³¹P NMR (162 MHz, CDCl₃) spectrum of **3ba-d2**



¹H NMR (400 MHz, CDCl₃) spectrum of **3ca**



¹³C NMR (100.6 MHz, CDCl₃) spectrum of **3ca**



³¹P NMR (162 MHz, CDCl₃) spectrum of **3ca**



¹H NMR (400 MHz, CDCl₃) spectrum of **3da**



¹³C NMR (100.6 MHz, CDCl₃) spectrum of **3da**



³¹P NMR (162 MHz, CDCl₃) spectrum of **3da**



¹H NMR (400 MHz, CDCl₃) spectrum of **3ea-d1**



¹³C NMR (100.6 MHz, CDCl₃) spectrum of **3ea-d1**



³¹P NMR (162 MHz, CDCl₃) spectrum of **3ea-d1**



¹H NMR (400 MHz, CDCl₃) spectrum of **3ea-d2**



¹³C NMR (100.6 MHz, CDCl₃) spectrum of **3ea-d2**



³¹P NMR (162 MHz, CDCl₃) spectrum of **3ea-d2**



¹H NMR (400 MHz, CDCl₃) spectrum of **3fa-d1**



¹³C NMR (100.6 MHz, CDCl₃) spectrum of **3fa-d1**



³¹P NMR (162 MHz, CDCl₃) spectrum of **3fa-d1**



¹H NMR (400 MHz, CDCl₃) spectrum of **3fa-d2**



¹³C NMR (100.6 MHz, CDCl₃) spectrum of **3fa-d2**


³¹P NMR (162 MHz, CDCl₃) spectrum of **3fa-d2**



¹H NMR (400 MHz, CDCl₃) spectrum of **3ab**



¹³C NMR (100.6 MHz, CDCl₃) spectrum of **3ab**



³¹P NMR (162 MHz, CDCl₃) spectrum of **3ab**



¹H NMR (400 MHz, CDCl₃) spectrum of **3ac**



¹³C NMR (100.6 MHz, CDCl₃) spectrum of **3ac**



³¹P NMR (162 MHz, CDCl₃) spectrum of **3ac**



¹H NMR (400 MHz, CDCl₃) spectrum of **3ad**



¹³C NMR (100.6 MHz, CDCl₃) spectrum of **3ad**



³¹P NMR (162 MHz, CDCl₃) spectrum of **3ad**



¹H NMR (400 MHz, CDCl₃) spectrum of **3ae**



¹³C NMR (100.6 MHz, CDCl₃) spectrum of **3ae**



³¹P NMR (162 MHz, CDCl₃) spectrum of **3ae**



¹H NMR (400 MHz, CDCl₃) spectrum of **3af**



¹³C NMR (100.6 MHz, CDCl₃) spectrum of **3af**



³¹P NMR (162 MHz, CDCl₃) spectrum of **3af**



¹H NMR (400 MHz, CDCl₃) spectrum of **3ag**



¹³C NMR (100.6 MHz, CDCl₃) spectrum of **3ag**



³¹P NMR (162 MHz, CDCl₃) spectrum of **3ag**



¹H NMR (400 MHz, CDCl₃) spectrum of **3ah**



¹³C NMR (100.6 MHz, CDCl₃) spectrum of **3ah**



³¹P NMR (162 MHz, CDCl₃) spectrum of **3ah**



¹H NMR (400 MHz, CDCl₃) spectrum of **3ai**



¹³C NMR (100.6 MHz, CDCl₃) spectrum of **3ai**



³¹P NMR (162 MHz, CDCl₃) spectrum of **3ai**



¹H NMR (400 MHz, CDCl₃) spectrum of **3aj**



¹³C NMR (100.6 MHz, CDCl₃) spectrum of **3aj**



³¹P NMR (162 MHz, CDCl₃) spectrum of **3aj**



¹H NMR (400 MHz, CD₃OD) spectrum of (*S*_P)-3aa-1



¹³C NMR (100.6 MHz, CD₃OD) spectrum of (*S*_P)-3aa-1



³¹P NMR (162 MHz, CD₃OD) spectrum of (*S*_P)-3aa-1



¹H NMR (400 MHz, CDCl₃) spectrum of (S_P)-3aa-2



¹³C NMR (100.6 MHz, CDCl₃) spectrum of (*S*_P)-3aa-2



³¹P NMR (162 MHz, CDCl₃) spectrum of (S_P)-3aa-2



¹H NMR (400 MHz, CDCl₃) spectrum of (S_P)-3aa-3



¹³C NMR (100.6 MHz, CDCl₃) spectrum of (*S*_P)-3aa-3


³¹P NMR (162 MHz, CDCl₃) spectrum of (S_P)-3aa-3



¹H NMR (400 MHz, CD₃OD) spectrum of (R_P)-3aa-1



¹³C NMR (100.6 MHz, CD₃OD) spectrum of (*R*_P)-3aa-1



³¹P NMR (162 MHz, CD₃OD) spectrum of (*R*_P)-3aa-1



¹H NMR (400 MHz, CDCl₃) spectrum of (*R*_P)-3aa-2



¹³C NMR (100.6 MHz, CDCl₃) spectrum of (*R*_P)-3aa-2



³¹P NMR (162 MHz, CDCl₃) spectrum of (*R*_P)-3aa-2



¹H NMR (400 MHz, CDCl₃) spectrum of (*R*_P)-3aa-3



¹³C NMR (100.6 MHz, CDCl₃) spectrum of (*R*_P)-3aa-3



³¹P NMR (162 MHz, CDCl₃) spectrum of (*R*_P)-3aa-3

■ Supplementary References ■

- Dadashi-Silab, S., Pan, X. & Matyjaszewski, K. Phenyl Benzo[b]phenothiazine as a Visible Light Photoredox Catalyst for Metal-Free Atom Transfer Radical Polymerization. *Chem. Eur. J.* 23, 5972–5977 (2017).
- (2) Watanabe, M. et al. Spacer effects in metal-free organic dyes for visible-light-driven dyesensitized photocatalytic hydrogen production. *J. Mater. Chem. A*, **2**, 12952–12961 (2014).
- (3) Ding, X. et al. Highly efficient phenothiazine 5,5-dioxide-based hole transport materials for planar perovskite solar cells with a PCE exceeding 20%. *J. Mater. Chem. A*, 7, 9510–9516 (2019).
- Münch, U. & Pfleiderer, W. Base-Labile Protecting Groups for the Oligoribonucleotide Synthesis. *Helv. Chim. Acta*, 84, 1504–1517 (2001).
- (5) Sekine, M. et al. Studies on Steric and Electronic Control of 2'-3' Phosphoryl Migration in 2'-Phosphorylated Uridine Derivatives and Its Application to the Synthesis of 2'-Phosphorylated Oligouridylates. J. Org. Chem. 61, 4087–4100 (1996).
- (6) Boers, R. B. et al. Synthesis and Spectroscopic Characterization of 1-¹³C- and 4-¹³C-Plastoquinone-9. *Eur. J. Org. Chem.* 2094–2108 (2002).
- (7) Gao, L. et al. Lewis Acid-Catalyzed Selective Reductive Decarboxylative Pyridylation of *N*-Hydroxyphthalimide Esters: Synthesis of Congested Pyridine-Substituted Quaternary Carbons. *ACS Catal.* 9, 10142–10151 (2019).
- (8) Luo, J. & Zhang, J. Donor–Acceptor Fluorophores for Visible-Light-Promoted Organic Synthesis: Photoredox/Ni Dual Catalytic C(sp³)–C(sp²) Cross-Coupling. ACS Catal. 6, 873–877 (2016).
- (9) Stemper, J. et al. Development of Chiral Phosphoric Acids based on Ferrocene-Bridged Paracyclophane Frameworks. *Adv. Synth. Catal.* **355**, 3613–3624 (2013).
- (10) Suzuki, M., Sekido, T., Matsuoka, S. & Takagi, K. Syntheses of Aliphatic Polycarbonates from 2'-Deoxyribonucleosides. *Biomacromolecules* **12**, 1449–1459 (2011).
- (11) Sheldrick, G. M. SHELXT integrated space-group and crystal-structure determination. *Acta Crystallogr.* A71, 3–8 (2015).
- (12) Sheldrick, G. M. Crystal structure refinement with SHELXL. Acta Crystallogr. C71, 3-8 (2015).
- (13)Dolomanov, O. V., Bourhis, L. J., Gildea, R. J., Howard, J. A. K. & Puschmann, H. Olex2: A complete structure solution, refinement and analysis program. *J. Appl. Crystallogr.* 42, 339–341 (2009).
- (14)Reich, D., Noble A., & Aggarwal V. K. Facile Conversion of α-Amino Acids into α-Amino Phosphonates by Decarboxylative Phosphorylation using Visible-Light Photocatalysis. *Angew. Chem.-Int. Ed.* **61**, e202207063 (2022).
- (15)Qing, X., TingTing, Z. & Libiao, H. Preparation method of large-steric-hindrance alkyl substituted phosphite diester. Patent no. CN110922427A (2020).
- (16)Meng, X. & Kim, S. Palladium(II)-Catalyzed Ortho-Arylation of Benzylic Phosphonic Monoesters Using Potassium Aryltrifluoroborates. J. Org. Chem. 78, 11247–11254 (2013).
- (17)Eagon, S. et al. Enantioselective reduction of α-substituted ketones mediated by the boronate ester TarB-NO₂. *Tetrahedron Letters*. **51**, 6418–6421 (2010).
- (18) Hayashi, R., Shimizu, A. & Yoshida, J. The Stabilized Cation Pool Method: Metal- and Oxidant-Free Benzylic C–H/Aromatic C–H Cross-Coupling. *J. Am. Chem. Soc.* **138**, 8400–8403 (2016).